{
  "letters": 741337,
  "pages": 178,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Ocugen, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 3,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Overview",
              "value": "This table appears to be a table of contents or index from a Form 10-K filing, which is an annual report required by the SEC. It lists various sections of the report, including business description, risk factors, financial statements, management discussion, corporate governance, and other regulatory disclosures. The table is organized by item numbers and their corresponding section descriptions, covering all major aspects of corporate reporting required in a Form 10-K."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 20,
          "title": "Product Description of COVAXIN and Other Vaccines",
          "data": [
            {
              "key": "Overview",
              "value": "Development of novel inhaled mucosal vaccine platform, including OCU500 (bivalent COVID-19 vaccine), OCU510 (seasonal quadrivalent flu vaccine), and OCU520 (combination flu and COVID-19 vaccine)."
            },
            {
              "key": "COVID-19 Overview",
              "value": "COVID-19 was first reported in Wuhan, China in December 2019, declared a global pandemic by WHO in March 2020. It is highly transmissible through respiratory droplets."
            },
            {
              "key": "Common Symptoms",
              "value": "Common symptoms include cough, shortness of breath, fever, and more."
            },
            {
              "key": "High Risks",
              "value": "Certain people, such as those over 65 and with underlying conditions, are at increased risk for severe illness."
            },
            {
              "key": "Variants of SARS-CoV-2",
              "value": "New variants emerge via gene mutations; Omicron variant raises concerns regarding transmissibility and vaccine efficacy."
            },
            {
              "key": "COVAXIN",
              "value": "COVAXIN is an inactivated SARS-CoV-2 vaccine designed to create a broad immune response, using specific adjuvants to enhance effectiveness."
            },
            {
              "key": "Dosing Regimen",
              "value": "Administered in two doses 28 days apart, shelf life of 24 months at 2-8Â°C."
            },
            {
              "key": "Immune Response",
              "value": "COVAXIN elicits both humoral and cellular immune responses, potentially providing long-term immunity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 25,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Competition Overview",
              "value": "We face intense competition from companies and institutions pursuing or commercializing COVID-19 vaccines."
            },
            {
              "key": "Competing Vaccines",
              "value": "Competitors include Pfizer/BioNTech, Moderna, AstraZeneca, Novavax, etc., with authorized vaccines in relevant territories."
            },
            {
              "key": "Manufacturing and Supply Relationships",
              "value": "Bilateral agreement with CanSinoBIO for gene therapy development, original 2019 agreement amended to include new products."
            },
            {
              "key": "Collaborative Efforts",
              "value": "Co-development for gene therapy platform is shared with CanSinoBIO, with defined territories for commercialization."
            },
            {
              "key": "Resource Competition",
              "value": "Many competitors may have better financial and R&D resources, affecting recruitment and trial participation."
            },
            {
              "key": "Mergers and Acquisitions Influence",
              "value": "Pharmaceutical sector mergers may consolidate resources among fewer competitors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 26,
          "title": "Clinical and Commercial Supply of COVAXIN",
          "data": [
            {
              "key": "Partnership with Bharat Biotech",
              "value": "Ocugen obtained an exclusive right and license to develop, manufacture, and commercialize COVAXIN."
            },
            {
              "key": "Manufacturing Partner",
              "value": "Jubilant HollisterStier selected as manufacturing partner."
            },
            {
              "key": "GMP Deficiencies",
              "value": "WHO identified GMP deficiencies in Bharat Biotech's facilities."
            },
            {
              "key": "Technology Transfer",
              "value": "Bharat Biotech will supply COVAXIN drug product components post technology transfer."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 27,
          "title": "Co-Development and Commercialization Agreement with CanSinoBIO",
          "data": [
            {
              "key": "Agreement Date",
              "value": "September 2019"
            },
            {
              "key": "Amendment Dates",
              "value": "September 2021, November 2022"
            },
            {
              "key": "Product Candidates",
              "value": "OCU400, OCU410, OCU410ST"
            },
            {
              "key": "Responsibilities",
              "value": "CanSinoBIO for CMC development and manufacture; royalty structure defined"
            },
            {
              "key": "Termination Conditions",
              "value": "Material breach, challenges to intellectual property, bankruptcy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 27,
          "title": "NeoCart License Agreement with Purpose",
          "data": [
            {
              "key": "Agreement Date",
              "value": "December 2005"
            },
            {
              "key": "Original License Agreement Date",
              "value": "August 2001"
            },
            {
              "key": "Technology",
              "value": "Sublicensed technology for cell/tissue cultivation"
            },
            {
              "key": "Royalty Obligations",
              "value": "Minimum royalties; low single digit royalties based on net sales"
            },
            {
              "key": "Total Payments Before Merger",
              "value": "$1.0 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 34,
          "title": "FDA Review Process",
          "data": [
            {
              "key": "Submission acceptance",
              "value": "FDA begins in-depth substantive review after submission is accepted for filing."
            },
            {
              "key": "PDUFA goals",
              "value": "FDA's goal to review 90% of new molecular entities within 10 months."
            },
            {
              "key": "Review process",
              "value": "Review may be extended if additional information is provided."
            },
            {
              "key": "Advisory committee referral",
              "value": "FDA may refer product candidates to an advisory committee."
            },
            {
              "key": "Approval Standards",
              "value": "FDA reviews applications for approval standards and manufacturing adequacy."
            },
            {
              "key": "Pre-Approval Inspection",
              "value": "FDA inspects facilities before approving marketing applications."
            },
            {
              "key": "Complete Response Letter",
              "value": "Indicates application is not ready for approval; outlines deficiencies."
            },
            {
              "key": "Resubmission options",
              "value": "Applicant may address deficiencies, withdraw, or request a hearing."
            },
            {
              "key": "Commercial marketing authorization",
              "value": "FDA issues approval letter allowing commercial marketing."
            },
            {
              "key": "Post-approval conditions",
              "value": "FDA may impose conditions post-approval such as further studies."
            },
            {
              "key": "Product withdrawal",
              "value": "FDA may withdraw approval if regulatory standards are not maintained."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 76,
          "title": "Risks Related to Collaborators",
          "data": [
            {
              "key": "risk_description",
              "value": "Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing."
            },
            {
              "key": "regulatory_applications",
              "value": "Collaborators could fail to make timely regulatory submissions for a product candidate."
            },
            {
              "key": "compliance_issues",
              "value": "Collaborators may not comply with all applicable regulatory requirements or may fail to report safety data."
            },
            {
              "key": "competition_and_collaboration",
              "value": "Collaborators could develop competing products independently or with third parties."
            },
            {
              "key": "marketing_commitments",
              "value": "Collaborators with marketing rights may not commit sufficient resources to marketing and distribution."
            },
            {
              "key": "collaboration_disputes",
              "value": "Disagreements with collaborators could cause delays, termination, or additional responsibilities."
            },
            {
              "key": "intellectual_property_risks",
              "value": "Collaborators may not maintain or defend intellectual property rights properly."
            },
            {
              "key": "third_party_infringement",
              "value": "Collaborators may infringe third parties' rights or fail to maintain licensed IP rights."
            },
            {
              "key": "termination_risks",
              "value": "Collaborations may be terminated for convenience, requiring additional capital."
            },
            {
              "key": "funding_reliance",
              "value": "Non-results from collaborations may affect funding, impacting product candidate development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 97,
          "title": "Dose-Escalation Clinical Trial of OCU400",
          "data": [
            {
              "key": "Subjects Enrolled",
              "value": "10"
            },
            {
              "key": "Maximum Tolerable Dose",
              "value": "High Dose"
            },
            {
              "key": "Phase 1/2 Trial Start Date",
              "value": "Second Quarter 2023"
            },
            {
              "key": "Phase 3 Trial Start Date",
              "value": "End of 2023"
            },
            {
              "key": "Indications",
              "value": "RP and LCA"
            },
            {
              "key": "IND Applications Submission Date",
              "value": "Second Quarter 2023"
            },
            {
              "key": "NeoCart Status",
              "value": "Phase 3-ready"
            },
            {
              "key": "NeoCart IND",
              "value": "Granted Regenerative Medicine Advanced Therapy Designation"
            },
            {
              "key": "NeoCart Phase 3 Start Date",
              "value": "First Half of 2024"
            },
            {
              "key": "COVAXIN Agreement",
              "value": "Co-Development, Supply and Commercialization Agreement with Bharat Biotech"
            },
            {
              "key": "COVAXIN Status",
              "value": "EUA in India for ages 6-18"
            },
            {
              "key": "COVAXIN Efficacy",
              "value": "77.8% overall, 93.4% against severe COVID-19"
            },
            {
              "key": "Phase 2/3 Results Announcement Date",
              "value": "January 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 114,
          "title": "Opinion on the Financial Statements",
          "data": [
            {
              "key": "Audit Firm",
              "value": "Independent Registered Public Accounting Firm"
            },
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Periods Audited",
              "value": "Years ended December 31, 2022 and 2021"
            },
            {
              "key": "Opinion Details",
              "value": "Consolidated financial statements present fairly, in all material respects, the financial position of the Company"
            },
            {
              "key": "Going Concern",
              "value": "Substantial doubt exists about the Company's ability to continue as a going concern"
            },
            {
              "key": "Audit Responsibility",
              "value": "Express an opinion on the Companyâs financial statements based on audits"
            },
            {
              "key": "Standards",
              "value": "Conducted in accordance with PCAOB standards"
            },
            {
              "key": "Critical Audit Matter",
              "value": "Matter arising from the current period audit that was communicated to the audit committee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 129,
          "title": "CanSinoBIO Agreement and Related Contracts",
          "data": [
            {
              "key": "License Model",
              "value": "Royalty"
            },
            {
              "key": "Royalty Rates to Company",
              "value": "mid- to high-single digits"
            },
            {
              "key": "Royalty Rates to CanSinoBIO",
              "value": "low- to mid-single digits"
            },
            {
              "key": "Termination Condition",
              "value": "Material breach, Bankruptcy, etc."
            },
            {
              "key": "Exclusive License with Washington University",
              "value": "Inhaled mucosal COVID-19 vaccine"
            },
            {
              "key": "Initial Fee Paid to Washington University",
              "value": "$1.0 million"
            },
            {
              "key": "Annual License Maintenance Fee",
              "value": "Variable"
            },
            {
              "key": "Development Milestones",
              "value": "Up to $37.0 million"
            },
            {
              "key": "Potential Royalty on Net Sales",
              "value": "Low single-digit percentage"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 140,
          "title": "Net Loss per Share of Common Stock",
          "data": [
            {
              "key": "Net loss â basic and diluted",
              "value": "-81,351"
            },
            {
              "key": "Shares used in calculating net loss per common share â basic and diluted",
              "value": "214,600,051"
            },
            {
              "key": "Net loss per common share â basic and diluted",
              "value": "-0.38"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 140,
          "title": "Equity Instruments Summary",
          "data": [
            {
              "key": "Options to purchase common stock",
              "value": "10,851,287"
            },
            {
              "key": "RSUs",
              "value": "924,810"
            },
            {
              "key": "Warrants",
              "value": "798,352"
            },
            {
              "key": "Series A Convertible Preferred Stock (as converted to common stock)",
              "value": "â"
            },
            {
              "key": "Series B Convertible Preferred Stock (as converted to common stock)",
              "value": "547,450"
            },
            {
              "key": "Total",
              "value": "13,121,899"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 161,
          "title": "First Amendment to the EXCLUSIVE LICENSE AGREEMENT",
          "data": [
            {
              "key": "Participants",
              "value": "The Washington University and Ocugen, Inc."
            },
            {
              "key": "Effective Date",
              "value": "Date of the last signature"
            },
            {
              "key": "License Agreement",
              "value": "WU Contract Number A2023-0203"
            },
            {
              "key": "Amendments",
              "value": "Modification of Territory, update of Patent Rights, incorporation of initial Development Plan"
            },
            {
              "key": "New Territory",
              "value": "US, Europe, Japan, South Korea, Australia, and China"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 169,
          "title": "Successor Clause and Entire Agreement",
          "data": [
            {
              "key": "Entity Involved",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Address",
              "value": "263 Great Valley Parkway, Malvern, PA 19355, USA"
            },
            {
              "key": "Attention",
              "value": "Shankar Musunuri"
            },
            {
              "key": "Governing Law",
              "value": "Delaware"
            },
            {
              "key": "Amendment Procedure",
              "value": "This Agreement may be amended...only by a written instrument executed by both parties."
            },
            {
              "key": "Waiver Procedures",
              "value": "The failure of either party to require performance...shall not affect the right to enforce later."
            },
            {
              "key": "Signatures",
              "value": "Counterparts may be executed."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 174,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Consent Details",
              "value": "Consent to the incorporation by reference in several Registration Statements for Ocugen, Inc."
            },
            {
              "key": "Registered Accounting Firm",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Location",
              "value": "Philadelphia, Pennsylvania"
            },
            {
              "key": "Report Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Registration Statements",
              "value": "1. Form S-3 No. 333-234127\n2. Form S-3 No. 333-237456\n3. Form S-3 No. 333-254550\n4. Form S-8 No. 333-237454 (Ocugen, Inc. 2019 Equity Incentive Plan)\n5. Form S-8 No. 333-254549 (Ocugen, Inc. 2019 Equity Incentive Plan)\n6. Form S-8 No. 333-263063 (Ocugen, Inc. Inducement Stock Option and Restricted Stock Unit Awards)\n7. Form S-8 No. 333-263064 (Ocugen, Inc. 2019 Equity Incentive Plan)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 14,
          "title": "Table of Contents and ERG Response Analysis",
          "data": [
            {
              "key": "image_content",
              "value": "Improved ERG responses in AAV8-Nr2e3 treated IRD retinas showing data analysis of scotopic and photopic ERG B-wave amplitudes."
            },
            {
              "key": "analysis_summary",
              "value": "Assessment of ERG B-wave amplitudes relative to treatment with AAV8-Nr2e3 in various mouse models."
            },
            {
              "key": "treatment_evaluation",
              "value": "Safety evaluation of Nr2e3 after subretinal administration in healthy mice with no observed detrimental effects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 46,
          "title": "Employee Development and Leadership",
          "data": [
            {
              "key": "Commitment to Employee Development",
              "value": "Continued learning and development is essential for retaining employees and fostering leadership."
            },
            {
              "key": "Diversity and Inclusion Commitment",
              "value": "Preserving and cultivating a diverse and inclusive workforce, particularly in leadership."
            },
            {
              "key": "Board Diversity",
              "value": "Board includes diverse members to comply with Nasdaq requirements."
            },
            {
              "key": "DEI Committee",
              "value": "Composed of diverse employees to promote diversity, equity, inclusion, and belonging."
            },
            {
              "key": "Employee Demographics",
              "value": "55% of employees are from ethnic and racial minority groups; 45% are women."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 89,
          "title": "Leadership Changes and Key Personnel Dependency",
          "data": [
            {
              "key": "Key Executive",
              "value": "Shankar Musunuri"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer, Chairman of the Board, and Co-Founder"
            },
            {
              "key": "Importance",
              "value": "Highly dependent on executive for research, development, and commercialization."
            },
            {
              "key": "Retention Challenge",
              "value": "Difficulty in replacing key employees."
            },
            {
              "key": "Employment Agreements",
              "value": "Exist but can be terminated at any time."
            },
            {
              "key": "Key Person Insurance",
              "value": "Not maintained for executives."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 111,
          "title": "Exhibits and Document References",
          "data": [
            {
              "key": "Exhibit",
              "value": "0.28+"
            },
            {
              "key": "Description",
              "value": "First Amendment to Amended and Restated Executive Employment Agreement, dated as of April 27, 2022, by and between Registrant and Shankar Musunuri (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q as filed on May 6, 2022)"
            },
            {
              "key": "Exhibit",
              "value": "0.29+"
            },
            {
              "key": "Description",
              "value": "and incorporated herein by reference) Amended and Restated Executive Employment Agreement, dated as of March 18, 2022, by and between the Registrant and Jessi Crespo (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q as filed on May 6, 2022)"
            },
            {
              "key": "Exhibit",
              "value": "0.30*+"
            },
            {
              "key": "Description",
              "value": "by reference) Amended and Restated Executive Employment Agreement, dated as of December 16, 2021, by and between the Registrant"
            },
            {
              "key": "Exhibit",
              "value": "0.31*+"
            },
            {
              "key": "Description",
              "value": "Arun Upadhyay First Amendment to Amended and Restated Executive Employment Agreement, dated as of August 26, 2022, by and between"
            },
            {
              "key": "Exhibit",
              "value": "0.32+"
            },
            {
              "key": "Description",
              "value": "Agreement dated as of June 22, 2012 between the Registrant and Purpose Co., Ltd. f/k/a Takagi Sangyo Co. Ltd. and f/k/a Takagi Industrial Co., Ltd. (filed as Exhibit 10.20 to the Registrant's Registration Statement on Form S-1 (SEC File No. 333-199202))"
            },
            {
              "key": "Exhibit",
              "value": "0.33+"
            },
            {
              "key": "Description",
              "value": "filed on October 7, 2014, and incorporated herein by reference) First Amendment to License Agreement, dated May 9, 2016, between the Registrant and Purpose Co., Ltd., f/k/a Takagi Sang Co. Ltd. (filed as Exhibit 10.33 to the Registrant's Quarterly Report on Form 10-Q as filed on August 11, 2016, and incorporated"
            },
            {
              "key": "Exhibit",
              "value": "21.1*"
            },
            {
              "key": "Description",
              "value": "List of Subsidiaries"
            },
            {
              "key": "Exhibit",
              "value": "23.1*"
            },
            {
              "key": "Description",
              "value": "Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm to the Registrant"
            },
            {
              "key": "Exhibit",
              "value": "31.1*"
            },
            {
              "key": "Description",
              "value": "Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Exhibit",
              "value": "31.2*"
            },
            {
              "key": "Description",
              "value": "Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Exhibit",
              "value": "32.1**"
            },
            {
              "key": "Description",
              "value": "Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350"
            },
            {
              "key": "Exhibit",
              "value": "101.INS*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Instance Document"
            },
            {
              "key": "Exhibit",
              "value": "101.SCH*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Schema Document"
            },
            {
              "key": "Exhibit",
              "value": "101.CAL*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Calculation Linkbase Document"
            },
            {
              "key": "Exhibit",
              "value": "101.DEF*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Definition Linkbase Document"
            },
            {
              "key": "Exhibit",
              "value": "101.LAB*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Label Linkbase Document"
            },
            {
              "key": "Exhibit",
              "value": "101.PRE*"
            },
            {
              "key": "Description",
              "value": "Inline XBRL Taxonomy Extension Presentation Linkbase Document"
            },
            {
              "key": "Exhibit",
              "value": "104"
            },
            {
              "key": "Description",
              "value": "The cover page from this Annual Report on Form 10-K, formatted in Inline XBRL"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 112,
          "title": "Signatures of Company Officers and Directors",
          "data": [
            {
              "key": "CEO",
              "value": "Shankar Musunuri"
            },
            {
              "key": "Chief Accounting Officer",
              "value": "Jessica Crespo"
            },
            {
              "key": "Director",
              "value": "Ramesh Kumar"
            },
            {
              "key": "Director",
              "value": "Junge Zhang"
            },
            {
              "key": "Director",
              "value": "Uday Kompella"
            },
            {
              "key": "Director",
              "value": "Kirsten Castillo"
            },
            {
              "key": "Director",
              "value": "Prabhavathi Fernandes"
            },
            {
              "key": "Director",
              "value": "Marna Whittington"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 145,
          "title": "Leadership Change Document",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Document Type",
              "value": "Agreement"
            },
            {
              "key": "Status",
              "value": "Executed"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 155,
          "title": "Leadership Change in Ocugen, Inc.",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Action",
              "value": "Executive Appointment"
            },
            {
              "key": "Date",
              "value": "(Date not specified)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 160,
          "title": "Executive Signature Details",
          "data": [
            {
              "key": "Person 1 Name",
              "value": "Dr. Shankar Musunuri"
            },
            {
              "key": "Person 1 Title",
              "value": "Chairman and CEO"
            },
            {
              "key": "Person 1 Date",
              "value": "11/21/2022"
            },
            {
              "key": "Person 2 Name",
              "value": "Shoubai Cl"
            },
            {
              "key": "Person 2 Title",
              "value": "CoO"
            },
            {
              "key": "Person 2 Date",
              "value": "11/18/2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 162,
          "title": "First Amendment to Agreement",
          "data": [
            {
              "key": "New Schedule B",
              "value": "Initial Development Plan [***]"
            },
            {
              "key": "Executed by",
              "value": "Nicole R. Mercier, PhD"
            },
            {
              "key": "Role",
              "value": "Asst. Vice Chancellor & Managing Director"
            },
            {
              "key": "Executed by",
              "value": "Dr. Shankar Musunuri"
            },
            {
              "key": "Role",
              "value": "Chairman and CEO"
            },
            {
              "key": "Signature Date (Mercier)",
              "value": "January 27, 2023"
            },
            {
              "key": "Signature Date (Musunuri)",
              "value": "January 31, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 170,
          "title": "Signature Page to Employment Agreement",
          "data": [
            {
              "key": "Company",
              "value": "OCUGEN, INC."
            },
            {
              "key": "Signatory Name",
              "value": "Shankar Musunuri, Ph.D., MBA"
            },
            {
              "key": "Title",
              "value": "Chairman and CEO"
            },
            {
              "key": "Employee Name",
              "value": "Arun Upadhyay, Ph.D."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 173,
          "title": "List of Wholly-Owned Subsidiaries",
          "data": [
            {
              "key": "Subsidiary Name",
              "value": "Ocugen Limited"
            },
            {
              "key": "Subsidiary Name",
              "value": "Ocugen OpCo, Inc."
            },
            {
              "key": "Subsidiary Name",
              "value": "Histogenics Securities Corporation"
            },
            {
              "key": "Subsidiary Name",
              "value": "Vaccigen Ltd."
            },
            {
              "key": "Subsidiary Name",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Jurisdiction",
              "value": "Ireland"
            },
            {
              "key": "Jurisdiction",
              "value": "Delaware"
            },
            {
              "key": "Jurisdiction",
              "value": "Massachusetts"
            },
            {
              "key": "Jurisdiction",
              "value": "Canada"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 176,
          "title": "Certification of Chief Accounting Officer",
          "data": [
            {
              "key": "name",
              "value": "Jessica Crespo"
            },
            {
              "key": "position",
              "value": "Chief Accounting Officer and Senior Vice President, Finance"
            },
            {
              "key": "report_type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "date",
              "value": "February 28, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 177,
          "title": "Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Document Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "February 28, 2023"
            },
            {
              "key": "CEO",
              "value": "Shankar Musunuri, Ph.D., MBA"
            },
            {
              "key": "CEO Title",
              "value": "Chief Executive Officer and Chairman (Principal Executive Officer)"
            },
            {
              "key": "CFO",
              "value": "Jessica Crespo, CPA"
            },
            {
              "key": "CFO Title",
              "value": "Chief Accounting Officer and Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 172,
          "title": "Amendment to Employment Agreement - Severance Payments",
          "data": [
            {
              "key": "Severance Payment Conditions",
              "value": "Employee will not be entitled to receive the Severance Payment or Change of Control Severance Payment unless Employee executes a release."
            },
            {
              "key": "Release Conditions",
              "value": "The Release will unconditionally release the Company and its shareholders from all claims."
            },
            {
              "key": "Payment Timing",
              "value": "The Severance Payment will begin as soon as practicable after the Release becomes irrevocable."
            },
            {
              "key": "Deferred Compensation Rules",
              "value": "If the payment is subject to Section 409A, it will not commence until the second taxable year."
            },
            {
              "key": "Effectivity Date",
              "value": "Changes are effective on the date of this Amendment."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 8,
          "title": "Novel Biologic Therapy for Retinal Diseases",
          "data": [
            {
              "key": "Product Candidate",
              "value": "OCU200"
            },
            {
              "key": "IND Application Submission to FDA",
              "value": "February 2023"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 1"
            },
            {
              "key": "Key Products",
              "value": "OCU400, OCU410, OCU410ST, OCU500, OCU510, OCU520"
            },
            {
              "key": "Focus Areas",
              "value": "DME, DR, wet AMD, RP, LCA, Stargardt disease, COVID-19 transmissions"
            },
            {
              "key": "Phase 1/2 Clinical Trial Start Date",
              "value": "Second quarter of 2023 for OCU400"
            },
            {
              "key": "Funding",
              "value": "Government funding for vaccine programs"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 17,
          "title": "Overview of Dry AMD and Stargardt Disease and Current Treatment Options",
          "data": [
            {
              "key": "Phase 1/2 clinical trial",
              "value": "Conducting a multicenter, open-label, dose-ranging study to assess the safety of unilateral subretinal administration of OCU400."
            },
            {
              "key": "FDA Approval",
              "value": "Intend to submit IND applications to initiate clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 19,
          "title": "NeoCart from Biopsy to Implantation",
          "data": [
            {
              "key": "Description",
              "value": "A process flow diagram showing the complete manufacturing and surgical procedure for NeoCart implantation, from initial biopsy to final implantation. The process is divided into two main phases: surgical steps and manufacturing steps, with manufacturing comprising four distinct stages of cell processing and cultivation."
            },
            {
              "key": "Surgical Steps",
              "value": "Assessment of defect and biopsy, Implantation into defect"
            },
            {
              "key": "Manufacturing Steps",
              "value": "Cell isolation and expansion, followed by seeding of 3D scaffold, Implant processing in bioreactor under joint-like conditions, Continued growth in static culture, NeoCart harvest and packaging"
            },
            {
              "key": "Step Count",
              "value": "Surgical: 2, Manufacturing: 4"
            },
            {
              "key": "Clinical Trials Information",
              "value": "NeoCart was acquired in our reverse merger in 2019 with Histogenics Corporation. Phase 1 and Phase 2 clinical trials were conducted to demonstrate the safety and efficacy of NeoCart, showing decreased pain and improved knee function. A Phase 3 clinical trial will be initiated in the first half of 2024."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 23,
          "title": "Overview of Novel Biologic Product Candidate for Retinal Diseases",
          "data": [
            {
              "key": "Product Name",
              "value": "OCU200"
            },
            {
              "key": "Indication",
              "value": "DR, DME, wet AMD"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 1"
            },
            {
              "key": "FDA IND Submission Date",
              "value": "February 2023"
            },
            {
              "key": "Study Design",
              "value": "multicenter, open-label, dose ranging study"
            },
            {
              "key": "Target Patient Population",
              "value": "participants with DME"
            },
            {
              "key": "Current Treatments for DME",
              "value": "anti-VEGF therapy, corticosteroids"
            },
            {
              "key": "Projected Population Effected by DR",
              "value": "162 million"
            },
            {
              "key": "Projected Population Effected by DME",
              "value": "21 million"
            },
            {
              "key": "Current Treatments for AMD",
              "value": "Ranibizumab, Aflibercept"
            },
            {
              "key": "Projected Population Effected by AMD",
              "value": "296 million"
            },
            {
              "key": "Percentage of AMD patients suffering from wet AMD",
              "value": "10%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 29,
          "title": "Executive Agreements and Licensing",
          "data": [
            {
              "key": "Agreement Details",
              "value": "Exclusive License Agreement with Washington University."
            },
            {
              "key": "Initial License Fee",
              "value": "$1.0 million"
            },
            {
              "key": "Potential Milestone Payments",
              "value": "up to $37.0 million"
            },
            {
              "key": "Royalty Structure",
              "value": "low single-digit percentage royalties on Net Sales."
            },
            {
              "key": "Expiration Conditions",
              "value": "The WU License Agreement will expire on a country-by-country and product-by-product basis."
            },
            {
              "key": "Termination Notice",
              "value": "90 days written notice for termination without cause."
            },
            {
              "key": "CU Agreement Contributions",
              "value": "Exclusive, worldwide, sublicensable license to patents for OCU200."
            },
            {
              "key": "Regulatory Milestone Payment",
              "value": "$1.5 million."
            },
            {
              "key": "Royalty on Sublicense Income",
              "value": "mid-teens percentage."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 45,
          "title": "Regulatory Compliance and Human Capital Management",
          "data": [
            {
              "key": "Clinical Testing Regulations",
              "value": "Health Canada and foreign jurisdictions may not accept clinical testing conducted under its regulation."
            },
            {
              "key": "Foreign Regulatory Approval",
              "value": "Obtaining approvals from regulatory authorities outside of the U.S. and Canada is necessary prior to clinical trials or marketing."
            },
            {
              "key": "Employee Count",
              "value": "As of February 15, 2023, the company had 84 employees."
            },
            {
              "key": "Employee Representation",
              "value": "None of the employees are represented by a labor union or covered by a collective bargaining agreement."
            },
            {
              "key": "Talent Management Goals",
              "value": "Focus on employee safety, wellness, engagement, development, diversity, inclusion, and compensation."
            },
            {
              "key": "Compensation Structure",
              "value": "Compensation programs are designed to align employee interests with business goals, including competitive salaries and benefits."
            },
            {
              "key": "Employee Benefits",
              "value": "Full-time employees are eligible for medical, dental, vision insurance, paid time off, a 401(k) plan, and more."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 103,
          "title": "Stock-based compensation",
          "data": [
            {
              "key": "Accounting standards",
              "value": "FASB ASC Topic 718"
            },
            {
              "key": "Types of awards",
              "value": "Stock options, restricted stock units (RSUs), preferred stock, and warrants"
            },
            {
              "key": "Recognition of expenses",
              "value": "Based on grant date fair values in consolidated statements of operations and comprehensive loss"
            },
            {
              "key": "Valuation model",
              "value": "Black-Scholes option-pricing model for options; market price of common stock for RSUs"
            },
            {
              "key": "Vesting conditions",
              "value": "Service-based vesting conditions recognized on a straight-line basis; performance-based conditions recognized when deemed probable"
            },
            {
              "key": "Contractual term of stock options",
              "value": "10 years"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 104,
          "title": "Stock-Based Compensation",
          "data": [
            {
              "key": "Stock-based compensation expense (2022)",
              "value": "$10.5 million"
            },
            {
              "key": "Stock-based compensation expense (2021)",
              "value": "$7.0 million"
            },
            {
              "key": "Unrecognized stock-based compensation expense",
              "value": "$14.9 million"
            },
            {
              "key": "Expected period for recognition",
              "value": "1.8 years"
            },
            {
              "key": "Expected dividend yield",
              "value": "0%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Executive Compensation",
          "data": [
            {
              "key": "incorporated_reference",
              "value": "Proxy Statement for our 2023 Annual Meeting of Stockholders"
            },
            {
              "key": "filing_intention",
              "value": "File with the SEC within 120 days after fiscal year-end"
            },
            {
              "key": "reporting_document",
              "value": "Annual Report on Form 10-K"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 110,
          "title": "Legal Agreements and Amendments Registry",
          "data": [
            {
              "key": "First Amendment to the Exclusive License Agreement",
              "value": "with The Regents of the University of Colorado and Ocugen Opco, Inc. (January 23, 2017)"
            },
            {
              "key": "Letter of Understanding",
              "value": "with The Regents of the University of Colorado and Ocugen Opco, Inc. (November 8, 2017)"
            },
            {
              "key": "Exclusive License Agreement",
              "value": "with The Schepens Eye Research Institute, Inc. and Co-Development Agreement with Bharat Biotech International Limited"
            },
            {
              "key": "First Amendment to Co-Development Agreement",
              "value": "with Bharat Biotech International Limited (May 29, 2021)"
            },
            {
              "key": "Second Amendment to Co-Development Agreement",
              "value": "with Bharat Biotech International Limited (April 15, 2022)"
            },
            {
              "key": "Development and Commercial Supply Agreement",
              "value": "with Bharat Biotech International Limited (September 29, 2021)"
            },
            {
              "key": "Co-Development and Commercialization Agreement",
              "value": "with CanSino Biologics Inc. (September 27, 2019)"
            },
            {
              "key": "First Amendment to Co-Development Agreement",
              "value": "with CanSino Biologics Inc. (September 30, 2021)"
            },
            {
              "key": "Second Amendment to Co-Development Agreement",
              "value": "with CanSino Biologics Inc. (November 21, 2022)"
            },
            {
              "key": "Exclusive License Agreement",
              "value": "with The Washington University (September 23, 2022)"
            },
            {
              "key": "First Amendment to License Agreement",
              "value": "with The Washington University (January 31, 2023)"
            },
            {
              "key": "Loan and Security Agreement",
              "value": "with EBS Life Sciences, LP and Ocugen Opco, Inc. (September 12, 2016)"
            },
            {
              "key": "Executive Employment Agreement",
              "value": "with Sanjay Subramanian (September 10, 2019)"
            },
            {
              "key": "Amendment to Executive Employment Agreement",
              "value": "with Sanjay Subramanian (January 1, 2020)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 126,
          "title": "Stock-Based Compensation",
          "data": [
            {
              "key": "Commencement Date",
              "value": "N/A"
            },
            {
              "key": "FASB ASC Topic",
              "value": "718"
            },
            {
              "key": "Recognized As",
              "value": "Research and Development expense or General and Administrative expense"
            },
            {
              "key": "Contractual Term of Stock Options",
              "value": "10 years"
            },
            {
              "key": "Vesting Period",
              "value": "1 to 3 years"
            },
            {
              "key": "Valuation Model",
              "value": "Black-Scholes"
            },
            {
              "key": "Assumptions Used",
              "value": "Expected Term, Stock Price Volatility, Risk-Free Interest Rate, Expected Dividends"
            },
            {
              "key": "Impact of Assumptions Change",
              "value": "Could materially differ future expense"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 128,
          "title": "Table of Contents and Recent Accounting Pronouncements",
          "data": [
            {
              "key": "Standard Issued",
              "value": "FASB ASU No. 2021-04, Earnings Per Share (Topic 260) and others"
            },
            {
              "key": "Effective Date",
              "value": "January 1, 2022"
            },
            {
              "key": "Impact on Financial Statements",
              "value": "Did not have a material impact"
            },
            {
              "key": "Recent Standard",
              "value": "FASB ASU No. 2020-06, Debt with Conversion and Other Options"
            },
            {
              "key": "Effective and Transition Date",
              "value": "January 1, 2024"
            },
            {
              "key": "Early Adoption",
              "value": "Permitted"
            },
            {
              "key": "Simplification",
              "value": "Eliminates separate accounting for embedded conversion features"
            },
            {
              "key": "New Disclosures Required",
              "value": "Events causing conversion contingencies and fair value of convertible debt"
            },
            {
              "key": "Impact on Financial Statements",
              "value": "Expected to have no material impact"
            },
            {
              "key": "Credit Loss Measurement Standard",
              "value": "FASB ASU No. 2016-13, Financial Instruments â Credit Losses"
            },
            {
              "key": "Effective Date for Credit Losses",
              "value": "January 1, 2023"
            },
            {
              "key": "Impact on Financial Statements",
              "value": "Expected to have no material impact"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Minimum Lease Payment Schedule",
          "data": [
            {
              "key": "Year",
              "value": "2023"
            },
            {
              "key": "Amount",
              "value": "763"
            },
            {
              "key": "Year",
              "value": "2024"
            },
            {
              "key": "Amount",
              "value": "787"
            },
            {
              "key": "Year",
              "value": "2025"
            },
            {
              "key": "Amount",
              "value": "810"
            },
            {
              "key": "Year",
              "value": "2026"
            },
            {
              "key": "Amount",
              "value": "834"
            },
            {
              "key": "Year",
              "value": "2027"
            },
            {
              "key": "Amount",
              "value": "834"
            },
            {
              "key": "Year",
              "value": "Thereafter"
            },
            {
              "key": "Amount",
              "value": "978"
            },
            {
              "key": "Year",
              "value": "Total"
            },
            {
              "key": "Amount",
              "value": "5006"
            },
            {
              "key": "Year",
              "value": "Less: present value adjustment"
            },
            {
              "key": "Amount",
              "value": "-921"
            },
            {
              "key": "Year",
              "value": "Present value of minimum lease payments"
            },
            {
              "key": "Amount",
              "value": "4085"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Debt Summary Comparison 2021-2022",
          "data": [
            {
              "key": "item",
              "value": "Principal outstanding"
            },
            {
              "key": "2022",
              "value": "2,000"
            },
            {
              "key": "2021",
              "value": "1,500"
            },
            {
              "key": "item",
              "value": "Plus: accrued interest"
            },
            {
              "key": "2022",
              "value": "307"
            },
            {
              "key": "2021",
              "value": "241"
            },
            {
              "key": "item",
              "value": "Less: unamortized debt issuance costs"
            },
            {
              "key": "2022",
              "value": "(18)"
            },
            {
              "key": "2021",
              "value": "(29)"
            },
            {
              "key": "item",
              "value": "Carrying value, net"
            },
            {
              "key": "2022",
              "value": "2,289"
            },
            {
              "key": "2021",
              "value": "1,712"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 136,
          "title": "General and Administrative Expenses Comparison",
          "data": [
            {
              "key": "General and administrative",
              "value": "Research and development"
            },
            {
              "key": "2022",
              "value": "2,764"
            },
            {
              "key": "2021",
              "value": "2,049"
            },
            {
              "key": "General and administrative",
              "value": "Total"
            },
            {
              "key": "2022",
              "value": "10,541"
            },
            {
              "key": "2021",
              "value": "6,958"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 137,
          "title": "Weighted average expected option term (years) and Stock Options Activity Summary",
          "data": [
            {
              "key": "Weighted average expected option term (years)",
              "value": "5.9"
            },
            {
              "key": "Range of expected stock price volatility",
              "value": "106% â 110%"
            },
            {
              "key": "Weighted average expected stock price volatility",
              "value": "107%"
            },
            {
              "key": "Range of risk-free interest rate",
              "value": "1.4% â 4.2%"
            },
            {
              "key": "Expected dividend rate",
              "value": "0%"
            },
            {
              "key": "Options outstanding at December 31, 2021",
              "value": "10,086,167"
            },
            {
              "key": "Granted",
              "value": "6,024,830"
            },
            {
              "key": "Exercised",
              "value": "-1,540,142"
            },
            {
              "key": "Forfeited",
              "value": "-3,719,568"
            },
            {
              "key": "Options outstanding at December 31, 2022",
              "value": "10,851,287"
            },
            {
              "key": "Options exercisable at December 31, 2022",
              "value": "2,950,927"
            },
            {
              "key": "Aggregate intrinsic value (2021)",
              "value": "24,664"
            },
            {
              "key": "Aggregate intrinsic value (2022)",
              "value": "1,385"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 139,
          "title": "Gross Unrecognized Tax Benefits Reconciliation",
          "data": [
            {
              "key": "Gross unrecognized tax benefits at beginning of year",
              "value": "$ 303"
            },
            {
              "key": "Additions for tax positions taken in a prior year",
              "value": "â"
            },
            {
              "key": "Additions for tax positions taken in the current year",
              "value": "â"
            },
            {
              "key": "Reductions for tax positions taken in the prior year due to settlement",
              "value": "â"
            },
            {
              "key": "Reductions for tax positions taken in the prior year due to statutes lapsing",
              "value": "â"
            },
            {
              "key": "Gross unrecognized tax benefits at end of year",
              "value": "$ 303"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 142,
          "title": "Incentive Stock Option Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Incentive Plan",
              "value": "2019 Equity Incentive Plan"
            },
            {
              "key": "Optionee",
              "value": "______________"
            },
            {
              "key": "Option Shares",
              "value": "______________"
            },
            {
              "key": "Option Price",
              "value": "_____ per share"
            },
            {
              "key": "Vesting Schedule",
              "value": "[insert vesting schedule]"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 143,
          "title": "Details on Stock Option Agreement and Vesting Conditions",
          "data": [
            {
              "key": "Option Termination Period",
              "value": "10 years from Grant Date (5 years if owning more than 10% voting power)"
            },
            {
              "key": "Cessation of Service",
              "value": "Option expires immediately upon cessation of services, unless due to death or total disability."
            },
            {
              "key": "Termination for Cause",
              "value": "Immediate termination upon cessation if due to Cause as defined."
            },
            {
              "key": "Change in Control",
              "value": "Option shall vest 100% immediately in the event of Change in Control."
            },
            {
              "key": "Rights as Stockholder",
              "value": "No rights until shares are issued."
            },
            {
              "key": "Nontransferability",
              "value": "Option is not transferable except by will."
            },
            {
              "key": "Securities Restrictions",
              "value": "Option Shares must comply with securities laws and may be restricted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 144,
          "title": "Executive Option Agreement",
          "data": [
            {
              "key": "Right to Continued Service",
              "value": "No right to continued employment or service with the Company."
            },
            {
              "key": "Provisions of Plan",
              "value": "Govern the provisions of the Plan."
            },
            {
              "key": "Administration",
              "value": "Full power to interpret and apply the provisions of this Agreement."
            },
            {
              "key": "Company Policies",
              "value": "Subject to policies regarding clawbacks, securities trading, etc."
            },
            {
              "key": "Certain Dispositions of Option Shares",
              "value": "Tax rules not applicable for certain dispositions."
            },
            {
              "key": "Governing Law",
              "value": "Laws of the State of Delaware."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 146,
          "title": "Non-Qualified Stock Option Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Plan",
              "value": "Ocugen, Inc. 2019 Equity Incentive Plan"
            },
            {
              "key": "Option Shares",
              "value": "______________"
            },
            {
              "key": "Option Price",
              "value": "_____ per share"
            },
            {
              "key": "Vesting Schedule",
              "value": "[insert vesting schedule]"
            },
            {
              "key": "Option Termination",
              "value": "10 years from the Grant Date"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 147,
          "title": "Stock Option Agreement Terms and Conditions",
          "data": [
            {
              "key": "Termination of Option",
              "value": "The exercisable portion of the Option will terminate three months after cessation of service, unless terminated or exercised sooner."
            },
            {
              "key": "Cause Definition",
              "value": "Includes refusal to perform duties, gross negligence, misconduct, fraud, felony conviction, or breach of agreement."
            },
            {
              "key": "Change in Control",
              "value": "Options become immediately vested and exercisable with respect to 100% of Option Shares."
            },
            {
              "key": "Rights as Stockholder",
              "value": "No rights as stockholder until shares are issued."
            },
            {
              "key": "Nontransferability",
              "value": "Options are not assignable or transferable except by will or descent."
            },
            {
              "key": "Securities Restrictions",
              "value": "Conditions apply if the registration statement is not in effect."
            },
            {
              "key": "No Right to Continued Service",
              "value": "No guaranteed employment or service rights."
            },
            {
              "key": "Provisions of Plan",
              "value": "Plan provisions govern in case of inconsistencies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Executive Compensation Agreement",
          "data": [
            {
              "key": "Administration",
              "value": "The Board or the committee appointed by the Board to administer the Plan, if any, will have full power and authority to interpret and apply the provisions of this Agreement."
            },
            {
              "key": "Company Policies",
              "value": "Optionee agrees, in consideration for the grant of the Option, to be subject to any policies of the Company regarding clawbacks, securities trading and hedging or pledging of securities."
            },
            {
              "key": "Miscellaneous",
              "value": "This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns."
            },
            {
              "key": "Governing Law",
              "value": "This Agreement shall be governed by the laws of the State of Delaware."
            },
            {
              "key": "Entire Agreement",
              "value": "This Agreement and the Plan constitute the entire agreement between the parties with respect to the subject matter."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 149,
          "title": "OCUGEN, INC. 2019 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT",
          "data": [
            {
              "key": "Participant",
              "value": "Shankar Musunuri"
            },
            {
              "key": "Grant Date",
              "value": "N/A"
            },
            {
              "key": "Total Number of Restricted Stock Units",
              "value": "N/A"
            },
            {
              "key": "Vesting Schedule",
              "value": "N/A"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 150,
          "title": "Restricted Stock Unit Agreement",
          "data": [
            {
              "key": "Award of Restricted Stock Units",
              "value": "The number of Restricted Stock Units granted to the Participant as per the Grant Notice."
            },
            {
              "key": "Date of Grant",
              "value": "The Restricted Stock Units were granted on the date specified in the Grant Notice."
            },
            {
              "key": "Vesting of Restricted Stock Units",
              "value": "Subject to continued service, the Units vest as defined in the Grant Notice."
            },
            {
              "key": "Effect of Termination of Service",
              "value": "Unvested Restricted Stock Units are forfeited upon cessation of service."
            },
            {
              "key": "Change in Control-Vesting Acceleration",
              "value": "Unvested portion becomes 100% vested upon a Change in Control."
            },
            {
              "key": "Settlement of Restricted Stock Units",
              "value": "Shares issued within sixty days following the vesting date."
            },
            {
              "key": "Non-Transferability",
              "value": "Restricted Stock Units cannot be transferred, assigned, or disposed of."
            },
            {
              "key": "Investment Representations",
              "value": "Participant acquires Restricted Stock Units for investment purposes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 151,
          "title": "Restricted Stock Units Agreement",
          "data": [
            {
              "key": "Acknowledge Tax Liability",
              "value": "The Participant acknowledges that the Company has not advised the Participant regarding the Participantâs income tax liability in connection with the grant of the Restricted Stock Units."
            },
            {
              "key": "Responsibility for Tax Liabilities",
              "value": "The Participant understands that they will be responsible for their own tax liabilities arising in connection with the Restricted Stock Units."
            },
            {
              "key": "No Guarantee of Employment",
              "value": "The Plan or Agreement will not confer a right to continue employment with the Company."
            },
            {
              "key": "Withholding Authorization",
              "value": "The Company may withhold any taxes required in connection with the Restricted Stock Units."
            },
            {
              "key": "Agreement to Company Policies",
              "value": "The Participant agrees to be subject to the Company's policies regarding clawback and securities trading."
            },
            {
              "key": "Familiarity with the Plan",
              "value": "The Participant has read the Plan and accepts the Restricted Stock Units subject to its terms."
            },
            {
              "key": "Entire Agreement Clause",
              "value": "The Grant Notice and Agreement, along with the Plan, represent the entire agreement between the parties."
            },
            {
              "key": "Amendment Conditions",
              "value": "Agreement may only be amended by a writing signed by both parties."
            },
            {
              "key": "Governing Law",
              "value": "Agreement will be construed in accordance with the laws of the State of Delaware."
            },
            {
              "key": "Execution of Grant Notice",
              "value": "The Grant Notice may be executed in one or more counterparts, each deemed original."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 152,
          "title": "OCUGEN, INC. NON-QUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT",
          "data": [
            {
              "key": "Type of Agreement",
              "value": "Non-Qualified Stock Option Inducement Award"
            },
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Grant Date",
              "value": "___________"
            },
            {
              "key": "Optionee",
              "value": "_______________"
            },
            {
              "key": "Number of Shares",
              "value": "________________"
            },
            {
              "key": "Option Price",
              "value": "____"
            },
            {
              "key": "Vesting Schedule",
              "value": "[insert vesting schedule]"
            },
            {
              "key": "Expiration",
              "value": "10 years from Grant Date"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 153,
          "title": "Termination of Option and Change in Control",
          "data": [
            {
              "key": "Termination Conditions",
              "value": "If Optionee ceases to perform services, any unexercisable portion expires immediately. Exercisable portion terminates after 3 months unless due to death or disability."
            },
            {
              "key": "Cause Definition",
              "value": "Defined as failure to perform duties, gross negligence, misconduct, fraud, or felony conviction."
            },
            {
              "key": "Change in Control Impact",
              "value": "The Option becomes fully vested and exercisable."
            },
            {
              "key": "Nontransferability",
              "value": "Options are not assignable except by will or laws of descent."
            },
            {
              "key": "Securities Restrictions",
              "value": "Option Shares may be subject to restrictions on transfer and may not be registered."
            },
            {
              "key": "Right to Service",
              "value": "No right to continued service with the Company."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 154,
          "title": "Receipt of Plan and Agreement Terms",
          "data": [
            {
              "key": "Acknowledgment of Receipt",
              "value": "Optionee acknowledges receipt of a copy of the Plan prior to the execution of this Agreement."
            },
            {
              "key": "Administration Body",
              "value": "The Board or the committee appointed by the Board to administer the Plan."
            },
            {
              "key": "Power and Authority",
              "value": "Full power and authority to interpret and apply the provisions of this Agreement."
            },
            {
              "key": "Company Policies",
              "value": "Subject to Company policies regarding clawbacks, securities trading and hedging or pledging of securities."
            },
            {
              "key": "Governing Law",
              "value": "The laws of the State of Delaware."
            },
            {
              "key": "Binding Effect",
              "value": "This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 156,
          "title": "OCUGEN, INC. RESTRICTED STOCK UNIT GRANT NOTICE",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Grant Type",
              "value": "Restricted Stock Units"
            },
            {
              "key": "Inducement Grant",
              "value": "Yes"
            },
            {
              "key": "Plan",
              "value": "2019 Equity Incentive Plan"
            },
            {
              "key": "Participant Agrees To",
              "value": "Terms of the Plan, the Agreement and this Grant Notice"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit A"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "Restricted Stock Unit Inducement Award Agreement",
          "data": [
            {
              "key": "Award type",
              "value": "Inducement grant"
            },
            {
              "key": "Plan",
              "value": "2019 Equity Incentive Plan"
            },
            {
              "key": "Date of Grant",
              "value": "As set forth in the Grant Notice"
            },
            {
              "key": "Vesting conditions",
              "value": "Subject to continued service of the Participant through vesting dates"
            },
            {
              "key": "Change in Control provision",
              "value": "Unvested portions become fully vested upon Change in Control"
            },
            {
              "key": "Settlement timeframe",
              "value": "Shares issued within 60 days after vesting"
            },
            {
              "key": "Non-transferability",
              "value": "Restricted Stock Units may not be sold or transferred"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 158,
          "title": "Investment Representations and Terms of Agreement",
          "data": [
            {
              "key": "Restricted Stock Units Acquisition",
              "value": "The Participant is acquiring the Restricted Stock Units for investment."
            },
            {
              "key": "Tax Consequences Responsibility",
              "value": "Participant acknowledges responsibility for their own tax liabilities."
            },
            {
              "key": "No Right to Employment Continuation",
              "value": "Participation does not confer any right to continue employment with the Company."
            },
            {
              "key": "Withholding Authorization",
              "value": "Participant authorizes the Company to withhold necessary taxes."
            },
            {
              "key": "Company Policies Compliance",
              "value": "The Participant agrees to comply with Company policies regarding clawback and securities."
            },
            {
              "key": "Acceptance of Plan Terms",
              "value": "The Participant accepts the Restricted Stock Units subject to Plan terms."
            },
            {
              "key": "Entire Agreement Clause",
              "value": "This Agreement represents the entire agreement regarding the subject."
            },
            {
              "key": "Amendment Clause",
              "value": "The Agreement can only be amended by written consent of parties."
            },
            {
              "key": "Governing Law",
              "value": "Agreement governed by the laws of Delaware."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 163,
          "title": "Amended & Restated Executive Employment Agreement",
          "data": [
            {
              "key": "Effective Date",
              "value": "December 16, 2021"
            },
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Employee",
              "value": "Arun Upadhyay, Ph.D."
            },
            {
              "key": "Prior Agreement Date",
              "value": "March 8, 2021"
            },
            {
              "key": "Base Compensation",
              "value": "Annual rate of compensation as set forth in Section 4.1, adjustable"
            },
            {
              "key": "Definition of Cause",
              "value": "Failure to perform material duties, misconduct, or fraudulent conduct"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 165,
          "title": "Executive Compensation Agreement Summary",
          "data": [
            {
              "key": "Effective Date",
              "value": "December 16, 2021"
            },
            {
              "key": "Position",
              "value": "Senior Vice President, Research & Development (SVP R&D)"
            },
            {
              "key": "Base Compensation",
              "value": "$375,000"
            },
            {
              "key": "Bonus Structure",
              "value": "Up to 40% of Base Compensation based on performance"
            },
            {
              "key": "Bonus Payment Deadline",
              "value": "February 28th"
            },
            {
              "key": "Travel Requirement",
              "value": "Up to 50% of working time"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 166,
          "title": "Fringe Benefits and Termination Conditions",
          "data": [
            {
              "key": "Employee Benefits",
              "value": "Eligible for reimbursement of reasonable expenses and participation in benefit plans, including pension and insurance."
            },
            {
              "key": "Termination Conditions",
              "value": "Employment terminates on death or disability, with specific payment entitlements upon termination."
            },
            {
              "key": "Severance Payment",
              "value": "Includes current Base Compensation and COBRA premium coverage."
            },
            {
              "key": "Change of Control Severance Payment",
              "value": "Enhanced severance compensation if employment is terminated around a Change of Control."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 167,
          "title": "Executive Severance and Compensation Terms",
          "data": [
            {
              "key": "Severance Payment Conditions",
              "value": "Employee must execute a release to receive payments."
            },
            {
              "key": "Claims Waived by Employee",
              "value": "Claims under Age Discrimination in Employment Act, Title VII, Civil Rights Act, and state laws."
            },
            {
              "key": "Payment Deferral Terms",
              "value": "Cash severance benefits are intended to meet Section 409A requirements."
            },
            {
              "key": "Indemnification Clause",
              "value": "Company indemnifies Employee against liabilities incurred in connection with 'Proceeding'."
            },
            {
              "key": "Golden Parachute Tax Provisions",
              "value": "As defined in company agreements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 168,
          "title": "Section 9: Change of Control and Excess Parachute Payments",
          "data": [
            {
              "key": "Change of Control Clause",
              "value": "Details provisions related to Change of Control events and excess parachute payments."
            },
            {
              "key": "Shareholder Approval Requirements",
              "value": "Payments conditioned on shareholder approval under Section 280G(b)(5)."
            },
            {
              "key": "Limitations on Payments",
              "value": "Employee entitled to receive Limited Amount or greater amount after tax reductions."
            },
            {
              "key": "Payment Reduction Order",
              "value": "Reductions will be made first to cash severance, then to bonuses, and then to equity vesting."
            },
            {
              "key": "Binding Nature of Agreement",
              "value": "Agreement binding upon Company, Affiliates, successors, and Employee's heirs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 171,
          "title": "Amendment #1 to Executive Employment Agreement",
          "data": [
            {
              "key": "Company",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Employee",
              "value": "Arun Upadhyay, Ph.D."
            },
            {
              "key": "Effective Date",
              "value": "September 1, 2022"
            },
            {
              "key": "Base Compensation",
              "value": "$420,000"
            },
            {
              "key": "Target Bonus",
              "value": "45% of Base Compensation"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 175,
          "title": "Certification by CEO Shankar Musunuri",
          "data": [
            {
              "key": "CEO Name",
              "value": "Shankar Musunuri, Ph.D., MBA"
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer and Chairman (Principal Executive Officer)"
            },
            {
              "key": "Date of Certification",
              "value": "February 28, 2023"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 11,
          "title": "Evaluation of Nr2e3 in Mouse Models of IRDs",
          "data": [
            {
              "key": "therapeutic approach",
              "value": "AAV8-Nr2e3 gene therapy"
            },
            {
              "key": "conditions treated",
              "value": "Inherited Retinal Diseases (IRDs)"
            },
            {
              "key": "study method",
              "value": "subretinal injection"
            },
            {
              "key": "number of models evaluated",
              "value": "5"
            },
            {
              "key": "principal finding",
              "value": "improved clinical, histological, functional, and molecular outcomes"
            },
            {
              "key": "note on gene therapy",
              "value": "mechanism involves resetting key retinal transcription factors"
            },
            {
              "key": "significance",
              "value": "demonstrates potential of modifier gene therapy to reduce retinal degeneration"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 12,
          "title": "Table of Contents and Fundus Imaging Results",
          "data": [
            {
              "key": "Process Description",
              "value": "The normal mouse retina is comprised of 10 to 12 layers of rod and cone photoreceptor nuclei in the ONL."
            },
            {
              "key": "Retina Recovery",
              "value": "rd1 retinas showed a profound rescue of photoreceptor cells (six to eight layers of ONL in early stage rescue IRD models) compared to the untreated eyes."
            },
            {
              "key": "Model Comparisons",
              "value": "Rho, Rhoâ/â P23H, and rd16 mice showed a more moderate increase (three to six layers) compared to untreated."
            },
            {
              "key": "Degeneration Timeline",
              "value": "ONL cell layer numbers in the rd7 model do not start degenerating until four to five months of age."
            },
            {
              "key": "Significance of Improvement",
              "value": "Retention of even a single layer of photoreceptor cells can maintain minimal visual function."
            },
            {
              "key": "Therapy Promise",
              "value": "Nr2e3 therapy has great promise in potentially restoring retinal development."
            },
            {
              "key": "Fundus Imaging Results",
              "value": "Considerable improvements were observed in the fundus of treated models, particularly rd16 and rd7."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 6,
          "title": "Product Launch Overview",
          "data": [
            {
              "key": "Modifier Gene Therapy Platform",
              "value": "Development of therapies addressing retinal diseases."
            },
            {
              "key": "Regenerative Medicine Cell Therapy Platform",
              "value": "NeoCart technology for knee cartilage repair."
            },
            {
              "key": "COVID-19 Vaccines",
              "value": "COVAXIN and novel inhaled mucosal vaccines for COVID-19."
            },
            {
              "key": "Novel Biologic Therapy for Retinal Diseases",
              "value": "OCU200 for diabetic eye conditions."
            },
            {
              "key": "Clinical Trials",
              "value": "OCU400 Phase 1/2 trial for RP and LCA in the USA."
            },
            {
              "key": "IND applications",
              "value": "Upcoming IND applications for OCU410 studies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 7,
          "title": "Product Launch of NeoCart and COVAXIN",
          "data": [
            {
              "key": "Product Name",
              "value": "NeoCart"
            },
            {
              "key": "Therapy Type",
              "value": "Cartilage Repair"
            },
            {
              "key": "FDA Designation",
              "value": "RMAT"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 3"
            },
            {
              "key": "Launch Date",
              "value": "First half of 2024"
            },
            {
              "key": "Vaccine Name",
              "value": "COVAXIN"
            },
            {
              "key": "Vaccine Efficacy",
              "value": "77.8% overall, 93.4% severe COVID-19"
            },
            {
              "key": "Target Population",
              "value": "Adults ages 18 years and older"
            },
            {
              "key": "Distribution Territories",
              "value": "United States, Canada, Mexico"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 9,
          "title": "NeoCart Manufacturing and Competitive Strengths Overview",
          "data": [
            {
              "key": "NeoCart Clinical Trial Material",
              "value": "Manufacturing for Phase 3 clinical trial material, intended to initiate in first half of 2024, subject to FDA discussions."
            },
            {
              "key": "Competitive Strengths",
              "value": "Experienced management team and esteemed scientific advisory boards with track record in biopharmaceuticals and vaccines."
            },
            {
              "key": "Manufacturing Partnerships",
              "value": "Partnerships established for clinical and commercial manufacturing with CanSino Biologics, Bharat Biotech, including other CDMO."
            },
            {
              "key": "Product Designations",
              "value": "OCU400 received ODD from the FDA and OMPD from the EC for treating NR2E3-related RP and LCA."
            },
            {
              "key": "Licensing and Development Arrangements",
              "value": "Licensing agreements with SERI, Purpose, Bharat Biotech, Washington University, and CU for various product candidates."
            },
            {
              "key": "Intellectual Property Portfolio",
              "value": "As of February 15, 2023, consists of 87 patents and 23 pending applications related to product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Product Pipeline Status",
          "data": [
            {
              "key": "Product Candidate",
              "value": "OCU400 AAV-hNR2E3"
            },
            {
              "key": "Indication",
              "value": "Gene mutation-associated retinal degeneration"
            },
            {
              "key": "Current Status",
              "value": "Phase 1/2"
            },
            {
              "key": "Product Candidate",
              "value": "OCU410 AAV-hRORA"
            },
            {
              "key": "Indication",
              "value": "Dry AMD"
            },
            {
              "key": "Current Status",
              "value": "IND planned for Q2 2023"
            },
            {
              "key": "Product Candidate",
              "value": "OCU410ST AAV-hRORA"
            },
            {
              "key": "Indication",
              "value": "Stargardt disease"
            },
            {
              "key": "Current Status",
              "value": "IND planned for Q2 2023"
            },
            {
              "key": "Product Candidate",
              "value": "NeoCart"
            },
            {
              "key": "Indication",
              "value": "Treatment of Articular Cartilage Defects in the Knee"
            },
            {
              "key": "Current Status",
              "value": "Phase 3 clinical trial first half of 2024, subject to discussions with the FDA"
            },
            {
              "key": "Product Candidate",
              "value": "COVAXINâ¢ (BBV152) SARS-CoV-2 virus"
            },
            {
              "key": "Indication",
              "value": "COVID-19"
            },
            {
              "key": "Current Status",
              "value": "Top line results show that the U.S. Phase 2/3 immuno-bridging and broadening clinical trial met both primary endpoints. Awaiting final data."
            },
            {
              "key": "Product Candidate",
              "value": "OCU500 Inhaled bivalent vaccine"
            },
            {
              "key": "Indication",
              "value": "COVID-19"
            },
            {
              "key": "Current Status",
              "value": ""
            },
            {
              "key": "Product Candidate",
              "value": "OCU510 Inhaled quadrivalent vaccine"
            },
            {
              "key": "Indication",
              "value": "Seasonal Flu"
            },
            {
              "key": "Current Status",
              "value": "Phase 1/2 to be initiated pending FDA discussions and government funding"
            },
            {
              "key": "Product Candidate",
              "value": "OCU520 Inhaled combination quadrivalent seasonal flu and bivalent COVID-19 vaccine"
            },
            {
              "key": "Indication",
              "value": "COVID-19 and Seasonal Flu"
            },
            {
              "key": "Current Status",
              "value": ""
            },
            {
              "key": "Product Candidate",
              "value": "OCU200 Transferrin - Tumstatin"
            },
            {
              "key": "Indication",
              "value": "DME, DR, Wet AMD"
            },
            {
              "key": "Current Status",
              "value": "IND submitted February 2023, IND-enabling, IND-enabling"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 13,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Figure 4",
              "value": "Hematoxylin/eosin (H/E) staining of AAV8-Nr2e3 early-stage rescues in IRD mouse models."
            },
            {
              "key": "Figure 5",
              "value": "H/E staining of AAV8-Nr2e3 advanced stage rescues in IRD mouse models."
            },
            {
              "key": "Study Overview",
              "value": "The visual function of Nr2e3 treated IRD retinas was examined in four out of five IRD strains."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "OCU400 Product Candidate for IRDs",
          "data": [
            {
              "key": "Product Name",
              "value": "OCU400"
            },
            {
              "key": "Description",
              "value": "Modifier gene therapy for retinal diseases."
            },
            {
              "key": "Mechanism",
              "value": "Restores retinal integrity and function through NR2E3 gene delivery."
            },
            {
              "key": "Development Status",
              "value": "Received ODD and OMPD designations."
            },
            {
              "key": "Target Conditions",
              "value": "Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA)."
            },
            {
              "key": "Mutations Addressed",
              "value": "NR2E3, RHO, CEP290, PDE6Ã, among other gene mutations."
            },
            {
              "key": "Expected Outcome",
              "value": "Improved visual outcomes and quality of life through gene therapy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 18,
          "title": "Product Development of NeoCart for Cartilage Repair",
          "data": [
            {
              "key": "Product Name",
              "value": "NeoCart"
            },
            {
              "key": "Product Description",
              "value": "NeoCart is a three-dimensional tissue-engineered disc of new cartilage designed to treat pain at the source, improve function, and potentially prevent a patient's progression to OA."
            },
            {
              "key": "Target Patient Demographic",
              "value": "Adults less than 55 years of age"
            },
            {
              "key": "Therapeutic Area",
              "value": "Cartilage damage in the knee"
            },
            {
              "key": "Manufacturing Process",
              "value": "Cells are derived from the patient and multiplied in a manufacturing facility, infused into a scaffold that supports tissue formation."
            },
            {
              "key": "Expected Benefits",
              "value": "Improved efficacy, long-term patient benefits, accelerated recovery, predictable outcomes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 22,
          "title": "Overview of the Seasonal Flu and Novel Inhaled Mucosal Vaccine Platform",
          "data": [
            {
              "key": "seasonal_flu_overview",
              "value": "An acute respiratory infection caused by influenza viruses."
            },
            {
              "key": "seasonal_flu_symptoms",
              "value": "Fever, dry cough, headache, muscle and joint pain, severe malaise, sore throat, runny nose."
            },
            {
              "key": "transmission",
              "value": "Spreads easily via droplets or physical contact."
            },
            {
              "key": "prevention_vaccine_percentage",
              "value": "Over 50% of the U.S. population above six months has received a flu shot."
            },
            {
              "key": "novel_vaccine_platform",
              "value": "Developing OCU500, OCU510, and OCU520 for COVID-19 and seasonal flu."
            },
            {
              "key": "vaccine_advantages",
              "value": "Needle-free, easier compliance, scalable manufacturing."
            },
            {
              "key": "oc520_design",
              "value": "Combination quadrivalent seasonal flu and bivalent COVID-19 vaccine."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 24,
          "title": "Launch of OCU200 for the Treatment of DR, DME, and Wet AMD",
          "data": [
            {
              "key": "Product Name",
              "value": "OCU200"
            },
            {
              "key": "Indications",
              "value": "Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (AMD)"
            },
            {
              "key": "Mechanism of Action",
              "value": "Fusion protein targeting leaky blood vessels and inhibiting new blood vessel growth"
            },
            {
              "key": "Active Components",
              "value": "Tumstatin and Transferrin"
            },
            {
              "key": "Proof of Concept",
              "value": "Demonstrated therapeutic potential in animal models for DR and AMD"
            },
            {
              "key": "Competitive Advantage",
              "value": "Targets multiple mechanisms, particularly for non-responders to existing therapies"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 31,
          "title": "Clinical Trials and IND Submission Process",
          "data": [
            {
              "key": "Approvals Required",
              "value": "Approval by an Institutional Review Board (IRB) for each clinical site before a trial initiation."
            },
            {
              "key": "Trial Requirements",
              "value": "Adequate and well-controlled human clinical trials to establish safety and efficacy."
            },
            {
              "key": "Manufacturing Processes",
              "value": "Development of manufacturing processes to ensure product quality and compliance with GMP."
            },
            {
              "key": "FDA Submission",
              "value": "Submission to the FDA of a New Drug Application (NDA) including preclinical testing results."
            },
            {
              "key": "FDA Review",
              "value": "FDA review and approval of NDA or BLA to allow commercial marketing."
            },
            {
              "key": "Preclinical Studies",
              "value": "Includes laboratory evaluations and animal studies for safety and efficacy."
            },
            {
              "key": "IND Submission",
              "value": "Submission of preclinical tests results, manufacturing info, and clinical protocols."
            },
            {
              "key": "Clinical Hold",
              "value": "FDA can impose clinical holds on trials due to safety concerns."
            },
            {
              "key": "IRB Approval",
              "value": "IRB must approve clinical trial plans and consent forms before study commences."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 33,
          "title": "Product Candidate Approval Process",
          "data": [
            {
              "key": "Phase 3 Trials",
              "value": "Typically, two Phase 3 trials are required by the FDA for product approval."
            },
            {
              "key": "Phase 4 Studies",
              "value": "These are referred to as Phase 4 studies and may be made a condition to be satisfied after approval."
            },
            {
              "key": "Manufacturing Process",
              "value": "The manufacturing process must be capable of consistently producing quality batches of the product candidate."
            },
            {
              "key": "NDA/BLA Submission",
              "value": "Assuming successful completion of the required clinical and preclinical testing, the results of product development are submitted to the FDA."
            },
            {
              "key": "User Fees",
              "value": "The submission of a marketing application is subject to a substantial application user fee."
            },
            {
              "key": "Orphan Products Fee Waiver",
              "value": "Product candidates that are designated as orphan products are also not subject to application user fees unless the application includes an indication other than the orphan indication."
            },
            {
              "key": "Pediatric Research Equity Act",
              "value": "Under PREA, a supplement to a BLA or NDA must contain adequate data to assess safety and effectiveness in pediatric subpopulations."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategy",
              "value": "The FDA may require submission of a REMS to ensure that the benefits of the product candidate outweigh the risks."
            },
            {
              "key": "FDA Review Time",
              "value": "Once the FDA receives an application, it generally takes 60 days to review the NDA or BLA to determine if it is substantially complete."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 54,
          "title": "Product Development and Regulatory Challenges",
          "data": [
            {
              "key": "Product Candidates",
              "value": "OCU400, OCU410, OCU410ST"
            },
            {
              "key": "Main Challenges",
              "value": "Achieve market acceptance, maintain safety and efficacy, obtain regulatory approval, manage manufacturing and distribution."
            },
            {
              "key": "Regulatory Agencies",
              "value": "FDA, EMA, NIH"
            },
            {
              "key": "Approval Impact",
              "value": "Delays or increased costs may arise from regulatory requirements."
            },
            {
              "key": "Technological Basis",
              "value": "Modifier gene therapy platform"
            },
            {
              "key": "Clinical Trial Needs",
              "value": "Must comply with IRB and IBC reviews."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 60,
          "title": "Orphan Drug Designation and Marketing Exclusivity",
          "data": [
            {
              "key": "Orphan designation",
              "value": "Obtained from FDA for OCU400 for NR2E3-related RP and LCA."
            },
            {
              "key": "Potential other designations",
              "value": "Seeking ODD or OMPD for other product candidates."
            },
            {
              "key": "Marketing exclusivity period",
              "value": "7 years in the United States, 10 years in Europe (may be reduced to 6 years under certain conditions)."
            },
            {
              "key": "Regulatory review impact",
              "value": "ODDs/OMPDs do not shorten the development or regulatory review time."
            },
            {
              "key": "Eligibility for designation",
              "value": "May be revoked if untrue statements or ineligible at time of submission."
            },
            {
              "key": "Regulatory exclusivity loss circumstances",
              "value": "Different indication upon approval, inability to assure sufficient product quantity."
            },
            {
              "key": "Clinical superiority requirement",
              "value": "Need to demonstrate clinical superiority if competing product is approved first."
            },
            {
              "key": "FDA designations",
              "value": "Pursuing fast track, breakthrough therapy, or RMAT designations."
            },
            {
              "key": "FDA granted designation",
              "value": "RMAT designation to NeoCart in May 2022 for knee cartilage repair."
            },
            {
              "key": "Designation benefit guarantees",
              "value": "No assurance of faster development or approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 66,
          "title": "Risks Related to the Commercialization of Our Product Candidates",
          "data": [
            {
              "key": "product_candidates",
              "value": "COVAXIN"
            },
            {
              "key": "EUA",
              "value": "received EUA in Mexico in adults ages 18 years and older."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 69,
          "title": "Market Acceptance Factors for Product Candidates",
          "data": [
            {
              "key": "competition",
              "value": "Competing products may not demonstrate sufficient clinical benefits compared to generics."
            },
            {
              "key": "market_acceptance",
              "value": "Depends on efficacy, safety, economic benefits, and reimbursement."
            },
            {
              "key": "challenges",
              "value": "Limited acceptance from physicians and patients for switching medications."
            },
            {
              "key": "ethical_concerns",
              "value": "Gene therapy faces ethical and legal challenges that may hinder acceptance."
            },
            {
              "key": "resources_needed",
              "value": "Significant resources required for education and marketing efforts."
            },
            {
              "key": "regulatory_impact",
              "value": "Regulatory approvals do not guarantee market acceptance."
            },
            {
              "key": "third_party_coverage",
              "value": "Need for adequate coverage and reimbursement from payors like Medicare."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 71,
          "title": "Risks Related to Our Dependence on Third Parties",
          "data": [
            {
              "key": "Risk Description",
              "value": "Increasingly strict third-party payor reimbursement policies could negatively impact revenue expectations for product candidates."
            },
            {
              "key": "Legislation Impact",
              "value": "The IRA includes drug pricing reforms that may reduce prices and reimbursement rates, impacting profitability."
            },
            {
              "key": "Dependence on Third Parties",
              "value": "Reliance on external parties for preclinical and clinical trials introduces risk of non-compliance and inadequate performance."
            },
            {
              "key": "Regulatory Responsibility",
              "value": "Firm remains responsible for compliance with applicable protocols and regulations despite reliance on third parties."
            },
            {
              "key": "Potential Issues",
              "value": "Contractual failures, regulatory non-compliance by third parties could delay approvals and commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 122,
          "title": "COVID-19 Vaccine Developments",
          "data": [
            {
              "key": "Co-Development Agreement with Bharat Biotech",
              "value": "The Company has a Co-Development, Supply and Commercialization Agreement with Bharat Biotech for COVAXIN."
            },
            {
              "key": "COVAXIN Description",
              "value": "COVAXIN is a whole-virion inactivated intramuscular COVID-19 vaccine."
            },
            {
              "key": "Clinical Trials Results",
              "value": "Top-line results from the Phase 2/3 clinical trial showed met co-primary immunogenicity endpoints."
            },
            {
              "key": "Emergency Use Authorization in Mexico",
              "value": "COVAXIN authorized for emergency use for adults aged 18 and older in Mexico."
            },
            {
              "key": "New Vaccine Development",
              "value": "Exclusive license obtained for inhaled mucosal COVID-19 vaccine with rights to develop, manufacture, and commercialize."
            },
            {
              "key": "New Vaccine Candidates",
              "value": "OCU500 (bivalent COVID-19), OCU510 (quadrivalent flu), OCU520 (combination flu and COVID-19)."
            },
            {
              "key": "IND Application for Retinal Therapy",
              "value": "IND application submitted to FDA in February 2023 for OCU200 therapy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 130,
          "title": "Ocugen Covaxin Territory and License Agreements",
          "data": [
            {
              "key": "License Agreement",
              "value": "Exclusive License Agreement with Bharat Biotech for commercialization of COVAXIN in the Ocugen territory."
            },
            {
              "key": "Profit Sharing",
              "value": "45% of profits retained by Ocugen, balance to Bharat Biotech."
            },
            {
              "key": "Responsibilities",
              "value": "Ocugen responsible for research, development, manufacturing, commercialization in Ocugen territory."
            },
            {
              "key": "Supply Agreement",
              "value": "Agreement with Bharat Biotech for supply of COVAXIN materials."
            },
            {
              "key": "SERI Agreement",
              "value": "Exclusive license to patent rights for NHR genes and related products."
            },
            {
              "key": "Royalty Payments",
              "value": "Low single-digit percentage royalties on annual net sales."
            },
            {
              "key": "Expiration",
              "value": "SERI Agreement expires on the last to expire licensed patent rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 131,
          "title": "Exclusive License Agreement with the University of Colorado",
          "data": [
            {
              "key": "Agreement Date",
              "value": "March 2014"
            },
            {
              "key": "Amendment Date",
              "value": "January 2017"
            },
            {
              "key": "Clarification Date",
              "value": "November 2017"
            },
            {
              "key": "License Details",
              "value": "Exclusive, worldwide, sublicensable license to patents for OCU200"
            },
            {
              "key": "Obligations of Company",
              "value": "Develop, manufacture, sublicense, market, and sell licensed products"
            },
            {
              "key": "Payment Milestones",
              "value": "$1.5 million for certain regulatory milestones"
            },
            {
              "key": "Royalty Details",
              "value": "Low single-digit percentage earned royalties on net sales and mid-teens on sublicense income"
            },
            {
              "key": "Termination Clause",
              "value": "Company may terminate with 60 days written notice; CU may terminate on breach or failure to pay"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 131,
          "title": "License Agreement with Purpose Co. Ltd.",
          "data": [
            {
              "key": "Original Agreement Date",
              "value": "December 2005"
            },
            {
              "key": "Original Agreement Details",
              "value": "Exclusive agreement to sublicense technology from Purpose Co. Ltd."
            },
            {
              "key": "Original License Agreement Date",
              "value": "August 2001"
            },
            {
              "key": "Minimum Royalty Paid",
              "value": "$1.0 million prior to reverse merger"
            },
            {
              "key": "Amendments Dates",
              "value": "June 2012; May 2016"
            },
            {
              "key": "Recent Changes",
              "value": "Company reacquired development and commercialization rights to NeoCart in Japan"
            },
            {
              "key": "Obligations of Company",
              "value": "Pay up to $10.0 million upon achievement of milestones and low single-digit royalties on sales in Japan."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 159,
          "title": "Second Amendment to the Co-Development and Commercialization Agreement",
          "data": [
            {
              "key": "Parties",
              "value": "Ocugen, Inc. and CanSino Biologics Inc."
            },
            {
              "key": "Effective Date",
              "value": "date of the last signature"
            },
            {
              "key": "Original Agreement Date",
              "value": "September 27, 2019"
            },
            {
              "key": "First Amendment Date",
              "value": "September 30, 2021"
            },
            {
              "key": "Amendment Summary",
              "value": "Addition of Stargardt disease to the definition of 'Field of OCU410'."
            },
            {
              "key": "Field of OCU410",
              "value": "Treatment of Dry Age-Related Macular Degeneration and Stargardt Disease."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 102,
          "title": "Funding requirements",
          "data": [
            {
              "key": "Funding requirements summary",
              "value": "We expect to incur significant expenses related to R&D, regulatory approvals, manufacturing, commercialization, and operational expansion."
            },
            {
              "key": "Current cash position",
              "value": "Approximately $90.9 million as of December 31, 2022."
            },
            {
              "key": "Funding needs",
              "value": "Will need to raise significant additional capital to fund operations until recognizing significant revenue."
            },
            {
              "key": "Potential funding strategies",
              "value": "Strategies may include public/private placements of equity/debt, grants, and licensing arrangements."
            },
            {
              "key": "Risks to funding",
              "value": "Risks include geopolitical turmoil, pandemic impacts, and uncertainty in estimated costs."
            },
            {
              "key": "Going concern",
              "value": "Substantial doubt about ability to continue as a going concern within one year."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 124,
          "title": "Cash and Cash Equivalents Statement",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "$77,563 (2022), $94,958 (2021)"
            },
            {
              "key": "Restricted cash",
              "value": "$0 (2022), $151 (2021)"
            },
            {
              "key": "Total cash, cash equivalents, and restricted cash",
              "value": "$77,563 (2022), $95,109 (2021)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 132,
          "title": "Assets by Level Classification",
          "data": [
            {
              "key": "assets",
              "value": "Total assets"
            },
            {
              "key": "valuation_date",
              "value": "December 31, 2022"
            },
            {
              "key": "total_assets",
              "value": "$90,934"
            },
            {
              "key": "cash_and_cash_equivalents",
              "value": "$71,563"
            },
            {
              "key": "level_1_assets",
              "value": "$76,564"
            },
            {
              "key": "level_2_assets",
              "value": "$14,370"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 132,
          "title": "Marketable Securities Analysis",
          "data": [
            {
              "key": "security_type",
              "value": "U.S. government agency securities and treasuries"
            },
            {
              "key": "amortized_cost",
              "value": "$7,432"
            },
            {
              "key": "unrealized_gains",
              "value": "$1"
            },
            {
              "key": "unrealized_losses",
              "value": "$0"
            },
            {
              "key": "fair_value",
              "value": "$7,433"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 132,
          "title": "Marketable Securities Analysis",
          "data": [
            {
              "key": "security_type",
              "value": "Commercial paper"
            },
            {
              "key": "amortized_cost",
              "value": "$5,938"
            },
            {
              "key": "unrealized_gains",
              "value": "$0"
            },
            {
              "key": "unrealized_losses",
              "value": "$0"
            },
            {
              "key": "fair_value",
              "value": "$5,938"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 2,
          "title": "Market Value of Common Stock",
          "data": [
            {
              "key": "aggregate market value",
              "value": "$483.2 million"
            },
            {
              "key": "outstanding shares",
              "value": "226,417,682"
            },
            {
              "key": "par value per share",
              "value": "$0.01"
            },
            {
              "key": "last day of fiscal quarter",
              "value": "June 30, 2022"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 50,
          "title": "Financial Forecast and Capital Requirements",
          "data": [
            {
              "key": "Current Cash Position",
              "value": "$90.9 million"
            },
            {
              "key": "Expected Funding Requirement",
              "value": "Substantial additional funding required over the next 12 months"
            },
            {
              "key": "Operational Funding Expectation",
              "value": "Enable us to fund operations into the first quarter of 2024"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Financial Operations Overview",
          "data": [
            {
              "key": "Net Loss (2022)",
              "value": "$81.4 million"
            },
            {
              "key": "Net Loss (2021)",
              "value": "$58.4 million"
            },
            {
              "key": "Accumulated Deficit as of December 31, 2022",
              "value": "$213.0 million"
            },
            {
              "key": "Cash, Cash Equivalents, and Investments Balance as of December 31, 2022",
              "value": "$90.9 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 100,
          "title": "Financial Performance Overview",
          "data": [
            {
              "key": "Net cash used in operating activities 2022",
              "value": "-60079"
            },
            {
              "key": "Net cash used in operating activities 2021",
              "value": "-47941"
            },
            {
              "key": "Net cash used in investing activities 2022",
              "value": "-16967"
            },
            {
              "key": "Net cash used in investing activities 2021",
              "value": "-1816"
            },
            {
              "key": "Net cash provided by financing activities 2022",
              "value": "59475"
            },
            {
              "key": "Net cash provided by financing activities 2021",
              "value": "120676"
            },
            {
              "key": "Effect of changes in exchange rate on cash, cash equivalents, and restricted cash 2022",
              "value": "25"
            },
            {
              "key": "Effect of changes in exchange rate on cash, cash equivalents, and restricted cash 2021",
              "value": "0"
            },
            {
              "key": "Net (decrease) increase in cash, cash equivalents, and restricted cash 2022",
              "value": "-17546"
            },
            {
              "key": "Net (decrease) increase in cash, cash equivalents, and restricted cash 2021",
              "value": "70919"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 101,
          "title": "Cash Flow Statement Analysis",
          "data": [
            {
              "key": "Cash used in operating activities (2022)",
              "value": "$60.1 million"
            },
            {
              "key": "Cash used in operating activities (2021)",
              "value": "$47.9 million"
            },
            {
              "key": "Cash used in investing activities (2022)",
              "value": "$17.0 million"
            },
            {
              "key": "Cash used in investing activities (2021)",
              "value": "$1.8 million"
            },
            {
              "key": "Cash provided by financing activities (2022)",
              "value": "$59.5 million"
            },
            {
              "key": "Cash provided by financing activities (2021)",
              "value": "$120.7 million"
            },
            {
              "key": "Future minimum operating lease obligations",
              "value": "$5.0 million"
            },
            {
              "key": "Indebtedness from EB-5 program",
              "value": "$2.0 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 113,
          "title": "Financial Statements Index",
          "data": [
            {
              "key": "Content",
              "value": "of Independent Registered Public Accounting Firm"
            },
            {
              "key": "Content",
              "value": "Consolidated Balance Sheets at December 31, 2022 and 2021"
            },
            {
              "key": "Content",
              "value": "Consolidated Statements of and Loss for the ended December 2022 and 2021"
            },
            {
              "key": "Content",
              "value": "Operations Comprehensive years 31,"
            },
            {
              "key": "Content",
              "value": "Consolidated Statements of Stockholders' Equity for the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Content",
              "value": "Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Content",
              "value": "Notes to the Consolidated Financial Statements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 115,
          "title": "Clinical Trial Accrual",
          "data": [
            {
              "key": "Clinical Trial Accrual Amount",
              "value": "$3.3 million"
            },
            {
              "key": "As of Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Complexity in Auditing",
              "value": "Estimation required by management in determining the progress to completion"
            },
            {
              "key": "Audit Procedures",
              "value": "Review of agreements with third-party vendors, testing of underlying data, confirmation of costs incurred"
            },
            {
              "key": "Auditor",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Audit Start Year",
              "value": "2018"
            },
            {
              "key": "Audit Date",
              "value": "February 28, 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 116,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Total assets",
              "value": "$108,632"
            },
            {
              "key": "Total liabilities",
              "value": "$24,580"
            },
            {
              "key": "Total stockholders' equity",
              "value": "$84,052"
            },
            {
              "key": "Current assets",
              "value": "$98,492"
            },
            {
              "key": "Accumulated deficit",
              "value": "-$213,018"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 117,
          "title": "Operating Expenses and Financial Results Comparison",
          "data": [
            {
              "key": "Operating expenses: Research and development",
              "value": "49,757"
            },
            {
              "key": "Operating expenses: General and administrative",
              "value": "35,111"
            },
            {
              "key": "Operating expenses: Total operating expenses",
              "value": "84,868"
            },
            {
              "key": "Operating expenses: Loss from operations",
              "value": "(84,868)"
            },
            {
              "key": "Operating expenses: Other income (expense), net",
              "value": "3,517"
            },
            {
              "key": "Operating expenses: Loss before income taxes",
              "value": "(81,351)"
            },
            {
              "key": "Operating expenses: Income tax benefit",
              "value": "0"
            },
            {
              "key": "Operating expenses: Net loss",
              "value": "(81,351)"
            },
            {
              "key": "Operating expenses: Foreign currency translation adjustment",
              "value": "25"
            },
            {
              "key": "Operating expenses: Unrealized gain (loss) on marketable securities",
              "value": "1"
            },
            {
              "key": "Operating expenses: Comprehensive loss",
              "value": "(81,325)"
            },
            {
              "key": "Operating expenses: Shares used in calculating net loss per common share",
              "value": "214,600,051"
            },
            {
              "key": "Operating expenses: Net loss per common share â basic and diluted",
              "value": "(0.38)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 118,
          "title": "Statement of Changes in Stockholders' Equity",
          "data": [
            {
              "key": "Balance at December 31, 2020",
              "value": "Total stockholders' equity was $21,550, with common shares totaling 184,133,384 and an accumulated deficit of (73,302)."
            },
            {
              "key": "Stock-based compensation expense",
              "value": "Increased additional paid-in capital by 6,958."
            },
            {
              "key": "Issuance of common stock for stock option and warrant exercises",
              "value": "1,381,799 shares issued totaling 1,262."
            },
            {
              "key": "Issuance of common stock for capital raises, net",
              "value": "13,987,000 shares issued totaling 119,459."
            },
            {
              "key": "Series B Convertible Preferred Stock issuance, net",
              "value": "Issued for 4,954."
            },
            {
              "key": "Net loss",
              "value": "The company reported a net loss of (58,365) in 2021."
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "Total stockholders' equity increased to 95,818, with common shares totaling 199,502,183."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 119,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Net loss",
              "value": "-81351"
            },
            {
              "key": "Depreciation and amortization expense",
              "value": "480"
            },
            {
              "key": "Amortization (accretion) on marketable securities",
              "value": "-99"
            },
            {
              "key": "Non-cash interest expense",
              "value": "83"
            },
            {
              "key": "Non-cash lease expense",
              "value": "593"
            },
            {
              "key": "Stock-based compensation expense",
              "value": "10541"
            },
            {
              "key": "Income tax benefit",
              "value": "null"
            },
            {
              "key": "Gain on forgiveness of Paycheck Protection Program note",
              "value": "0"
            },
            {
              "key": "Net cash used in investing activities",
              "value": "-16967"
            },
            {
              "key": "Net cash provided by financing activities",
              "value": "59475"
            },
            {
              "key": "Net (decrease) increase in cash, cash equivalents, and restricted cash",
              "value": "-17546"
            },
            {
              "key": "Cash, cash equivalents, and restricted cash at beginning of period",
              "value": "95109"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 120,
          "title": "Supplemental Disclosure of Non-Cash Investing and Financing Transactions",
          "data": [
            {
              "key": "transaction",
              "value": "Series B Convertible Preferred Stock issuance"
            },
            {
              "key": "2021_2",
              "value": "4,988"
            },
            {
              "key": "transaction",
              "value": "Exercise of warrants"
            },
            {
              "key": "2022_1",
              "value": "AAW"
            },
            {
              "key": "2021_1",
              "value": "AH"
            },
            {
              "key": "2021_2",
              "value": "603"
            },
            {
              "key": "transaction",
              "value": "Forgiveness of Paycheck Protection Program note"
            },
            {
              "key": "2021_2",
              "value": "426"
            },
            {
              "key": "transaction",
              "value": "Purchase of property and equipment"
            },
            {
              "key": "2022_2",
              "value": "911"
            },
            {
              "key": "2021_1",
              "value": "PRAA"
            },
            {
              "key": "2021_2",
              "value": "16"
            },
            {
              "key": "transaction",
              "value": "Right-of-use assets related to operating leases"
            },
            {
              "key": "2022_1",
              "value": "PRA"
            },
            {
              "key": "2022_2",
              "value": "2,916"
            },
            {
              "key": "2021_2",
              "value": "1,226"
            },
            {
              "key": "transaction",
              "value": "Debt issuance costs"
            },
            {
              "key": "2022_2",
              "value": "37"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 123,
          "title": "Financial Performance and Viability Assessment",
          "data": [
            {
              "key": "Accumulated Deficit",
              "value": "$213.0 million"
            },
            {
              "key": "Cash and Cash Equivalents",
              "value": "$90.9 million"
            },
            {
              "key": "Funding Requirement",
              "value": "Next 12 months"
            },
            {
              "key": "Funding Plan",
              "value": "Public and private placements of equity and/or debt, potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements, funding from third parties."
            },
            {
              "key": "Going Concern Doubt",
              "value": "Substantial doubt about the Company's ability to continue as a going concern within one year."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 125,
          "title": "Financial Instruments and Property & Equipment",
          "data": [
            {
              "key": "Impairments on Debt Securities",
              "value": "The Company did not recognize any impairments with respect to its debt securities during the year ended December 31, 2022."
            },
            {
              "key": "Investments in Debt Securities",
              "value": "The Company did not invest in debt securities prior to 2022."
            },
            {
              "key": "Concentration of Credit Risk",
              "value": "Financial instruments consist of cash and cash equivalents, held in accounts at financial institutions that may exceed federally insured limits."
            },
            {
              "key": "Credit Losses",
              "value": "The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk."
            },
            {
              "key": "Derivative Instruments",
              "value": "The Company evaluates financial instruments to determine if they are derivatives."
            },
            {
              "key": "Property and Equipment Definition",
              "value": "Property and equipment includes furniture, fixtures, machinery, equipment, leasehold improvements, and construction in progress."
            },
            {
              "key": "Depreciation Method",
              "value": "Depreciation is calculated using the straight-line method."
            },
            {
              "key": "Useful life of Machinery and Equipment",
              "value": "5 to 7 years"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 138,
          "title": "Loss before income taxes comparison 2021-2022",
          "data": [
            {
              "key": "Loss before income taxes 2022",
              "value": "-81,351"
            },
            {
              "key": "Loss before income taxes 2021",
              "value": "-58,417"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 138,
          "title": "Tax Rate Reconciliation",
          "data": [
            {
              "key": "Expected provision at statutory rate 2022",
              "value": "21.0%"
            },
            {
              "key": "Expected provision at statutory rate 2021",
              "value": "21.0%"
            },
            {
              "key": "State income tax, net of federal benefit 2022",
              "value": "74%"
            },
            {
              "key": "State income tax, net of federal benefit 2021",
              "value": "7.9%"
            },
            {
              "key": "Tax credits 2022",
              "value": "3.3%"
            },
            {
              "key": "Tax credits 2021",
              "value": "3.2%"
            },
            {
              "key": "Change in state tax rate 2022",
              "value": "(11.6)%"
            },
            {
              "key": "Change in state tax rate 2021",
              "value": "â%"
            },
            {
              "key": "Other, net 2022",
              "value": "(1.7)%"
            },
            {
              "key": "Other, net 2021",
              "value": "(0.1)%"
            },
            {
              "key": "Change in valuation allowance 2022",
              "value": "(18.4)%"
            },
            {
              "key": "Change in valuation allowance 2021",
              "value": "(31.9)%"
            },
            {
              "key": "Effective tax rate 2022",
              "value": "â%"
            },
            {
              "key": "Effective tax rate 2021",
              "value": "0.1%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 138,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Net operating loss carryforwards 2022",
              "value": "$51,884"
            },
            {
              "key": "Net operating loss carryforwards 2021",
              "value": "$52,038"
            },
            {
              "key": "Capital loss carryforwards 2022",
              "value": "$7,298"
            },
            {
              "key": "Capital loss carryforwards 2021",
              "value": "$7,298"
            },
            {
              "key": "Start-up costs 2022",
              "value": "$9,699"
            },
            {
              "key": "Start-up costs 2021",
              "value": "$11,235"
            },
            {
              "key": "Accruals and reserves 2022",
              "value": "$629"
            },
            {
              "key": "Accruals and reserves 2021",
              "value": "$448"
            },
            {
              "key": "Intellectual property 2022",
              "value": "$5,057"
            },
            {
              "key": "Intellectual property 2021",
              "value": "$1,960"
            },
            {
              "key": "Stock-based compensation 2022",
              "value": "$2,709"
            },
            {
              "key": "Stock-based compensation 2021",
              "value": "$2,064"
            },
            {
              "key": "Capitalization of research and development expense 2022",
              "value": "$10,379"
            },
            {
              "key": "Tax credits 2022",
              "value": "$6,655"
            },
            {
              "key": "Tax credits 2021",
              "value": "$4,350"
            },
            {
              "key": "Lease liabilities 2022",
              "value": "$1,029"
            },
            {
              "key": "Lease liabilities 2021",
              "value": "$461"
            },
            {
              "key": "Total deferred tax assets 2022",
              "value": "$95,339"
            },
            {
              "key": "Total deferred tax assets 2021",
              "value": "$79,854"
            },
            {
              "key": "Valuation allowance 2022",
              "value": "$-94,364"
            },
            {
              "key": "Valuation allowance 2021",
              "value": "$-79,395"
            },
            {
              "key": "Deferred tax assets, net of valuation allowance 2022",
              "value": "$975"
            },
            {
              "key": "Deferred tax assets, net of valuation allowance 2021",
              "value": "$459"
            },
            {
              "key": "Lease right-of-use assets 2022",
              "value": "$-975"
            },
            {
              "key": "Lease right-of-use assets 2021",
              "value": "$-459"
            },
            {
              "key": "Net deferred tax assets 2022",
              "value": "$0"
            },
            {
              "key": "Net deferred tax assets 2021",
              "value": "$0"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": false,
      "elements": []
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 52,
          "title": "Debt Obligations and Capital Raises",
          "data": [
            {
              "key": "Capital Raises",
              "value": "Public offering and at-the-market offering program"
            },
            {
              "key": "Outstanding Debt",
              "value": "$2.0 million under EB-5 Loan Agreement"
            },
            {
              "key": "Debt Secured By",
              "value": "Substantially all assets, excluding intellectual property"
            },
            {
              "key": "Challenges Due To Debt",
              "value": "Reduced cash flow available for operations and investments"
            },
            {
              "key": "Net Operating Loss Carryforwards",
              "value": "$200.5 million as of December 31, 2022"
            },
            {
              "key": "Tax Implications",
              "value": "Subject to Section 382 limitations due to ownership change"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 135,
          "title": "Equity Offerings of Common Stock",
          "data": [
            {
              "key": "Offering Type",
              "value": "At-the-Market Offerings"
            },
            {
              "key": "Shares Sold",
              "value": "4.7 million"
            },
            {
              "key": "Gross Sales Price",
              "value": "$160.0 million"
            },
            {
              "key": "Net Proceeds",
              "value": "$7.9 million"
            },
            {
              "key": "Issuance Costs",
              "value": "$0.4 million"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Registration Statement",
              "value": "Form S-3ASR"
            },
            {
              "key": "Additional Share Sale",
              "value": "Subsequent to December 31, 2022"
            },
            {
              "key": "Previous Year Sales",
              "value": "1.0 million shares"
            },
            {
              "key": "Previous Year Net Proceeds",
              "value": "$4.8 million"
            },
            {
              "key": "Previous Year Issuance Costs",
              "value": "$0.1 million"
            },
            {
              "key": "Public Offering Date",
              "value": "February 2022"
            },
            {
              "key": "Public Offering Shares Sold",
              "value": "16.0 million"
            },
            {
              "key": "Public Offering Price",
              "value": "$3.13"
            },
            {
              "key": "Public Offering Net Proceeds",
              "value": "$49.8 million"
            },
            {
              "key": "Registered Direct Offering Date",
              "value": "April 2021"
            },
            {
              "key": "Registered Direct Offering Shares Sold",
              "value": "10.0 million"
            },
            {
              "key": "Registered Direct Offering Price",
              "value": "$10.00"
            },
            {
              "key": "Registered Direct Offering Net Proceeds",
              "value": "$93.4 million"
            },
            {
              "key": "Registered Direct Offering Issuance Costs",
              "value": "$6.6 million"
            },
            {
              "key": "Previous Registered Direct Offering Date",
              "value": "February 2021"
            },
            {
              "key": "Previous Registered Direct Offering Shares Sold",
              "value": "3.0 million"
            },
            {
              "key": "Previous Registered Direct Offering Price",
              "value": "$7.65"
            },
            {
              "key": "Previous Registered Direct Offering Net Proceeds",
              "value": "$21.2 million"
            },
            {
              "key": "Previous Registered Direct Offering Issuance Costs",
              "value": "$1.7 million"
            },
            {
              "key": "COVAXIN Preferred Stock Purchase Agreement Date",
              "value": "March 1, 2021"
            },
            {
              "key": "Preferred Stock Shares Sold",
              "value": "0.1 million"
            },
            {
              "key": "Preferred Stock Price per Share",
              "value": "$109.60"
            },
            {
              "key": "Advance Payment",
              "value": "$6.0 million"
            },
            {
              "key": "Conversion Rate",
              "value": "10 shares of common stock per share of preferred stock"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 5,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Key personnel recruitment and retention",
              "value": "Our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers."
            },
            {
              "key": "Regulatory compliance",
              "value": "Our ability to comply with stringent government regulations regarding the manufacturing of pharmaceutical products."
            },
            {
              "key": "Health epidemics and outbreaks impact",
              "value": "The extent to which health epidemics and other outbreaks, including the COVID-19 pandemic, could disrupt our business."
            },
            {
              "key": "Geopolitical and economic turmoil",
              "value": "The impact of geopolitical turmoil, macroeconomic conditions, social unrest, political instability, terrorism, or acts of war."
            },
            {
              "key": "Forward-looking statements caution",
              "value": "Cautionary statements indicate that actual results may diverge materially from forward-looking statements due to numerous factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 42,
          "title": "Healthcare Reform Measures and Third-party Reimbursement Risks",
          "data": [
            {
              "key": "Overview",
              "value": "Healthcare payors and government programs may impose restrictions and price controls that affect reimbursement and pricing of product candidates."
            },
            {
              "key": "Risks",
              "value": "- Legislative reforms may lower reimbursements and exclude products from coverage."
            },
            {
              "key": "Cost Containment",
              "value": "Government and private payors are focused on controlling costs, which could significantly reduce revenues from sales."
            },
            {
              "key": "Challenges for Product Launch",
              "value": "Third-party reimbursement affects market acceptance and pricing strategies."
            },
            {
              "key": "Need for Economic Studies",
              "value": "Pharmacoeconomic studies may be necessary to demonstrate cost-effectiveness."
            },
            {
              "key": "Legislative Influence",
              "value": "Healthcare reform measures can affect product reimbursement and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Risk Factors Summary",
          "data": [
            {
              "key": "Investment Risk",
              "value": "Investing in our securities involves a high degree of risk."
            },
            {
              "key": "Significant Losses",
              "value": "We have incurred significant losses and negative cash flows from operations since our inception."
            },
            {
              "key": "Additional Funding Needs",
              "value": "We will need substantial additional funding."
            },
            {
              "key": "Dependence on Product Candidates",
              "value": "We are substantially dependent on the success of our product candidates."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "Our product candidates generated from our modifier gene therapy platform face an uncertain regulatory environment."
            },
            {
              "key": "Commercialization Challenges",
              "value": "We may be unable to successfully produce and commercialize a vaccine in a timely manner."
            },
            {
              "key": "Experience in Marketing Approvals",
              "value": "We have no experience in obtaining marketing approvals for products in Canada or Mexico."
            },
            {
              "key": "Clinical Trial Enrollment Delays",
              "value": "Delays in patient enrollment may hinder clinical trials."
            },
            {
              "key": "Competition",
              "value": "We face significant competition from other companies."
            },
            {
              "key": "Reimbursement Risk",
              "value": "If third-party payors do not reimburse patients, our ability to commercialize products will be harmed."
            },
            {
              "key": "Manufacturing and Supply Agreements",
              "value": "If we encounter difficulties in negotiating agreements with manufacturers, our product commercialization would be impaired."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 48,
          "title": "Risk Factors Related to Product Development and Management",
          "data": [
            {
              "key": "Delays in Development and Commercialization",
              "value": "Manufacturers may face delays in development and commercialization of product candidates."
            },
            {
              "key": "Collaboration Challenges",
              "value": "There is uncertainty in establishing or maintaining collaborative relationships for product development."
            },
            {
              "key": "Patent Protection Risks",
              "value": "Challenges in obtaining and maintaining patent protection for technology and product candidates."
            },
            {
              "key": "Lawsuits for Patent Protection",
              "value": "Potential involvement in lawsuits related to patent enforcement."
            },
            {
              "key": "Impact of Charter Documents",
              "value": "Provisions in company charter documents may discourage favorable takeovers."
            },
            {
              "key": "Stock Price Volatility",
              "value": "Trading prices may be highly volatile, leading to potential losses for stock purchasers."
            },
            {
              "key": "Dependence on Key Executives",
              "value": "Future success depends on retaining key executives and attracting qualified personnel."
            },
            {
              "key": "Financial Reporting Risks",
              "value": "Failure to maintain effective internal control over financial reporting may impair financial statement accuracy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Risks Related to Our Financial Position and Capital Requirements",
          "data": [
            {
              "key": "Financial Losses",
              "value": "Incurred significant losses and negative cash flows since inception, with net losses of approximately $81.4 million and $58.4 million for the years ended December 31, 2022 and 2021."
            },
            {
              "key": "Going Concern",
              "value": "Substantial doubt about the ability to continue as a going concern without obtaining significant additional funding."
            },
            {
              "key": "Capital Requirements",
              "value": "Estimated cash, cash equivalents, and investments will enable funding only into Q1 2024; significant additional capital needed."
            },
            {
              "key": "Revenue Generation",
              "value": "No revenues generated from product sales to date."
            },
            {
              "key": "Future Operations Risks",
              "value": "Ability to raise capital could be hindered by market perception and economic conditions."
            },
            {
              "key": "R&D Investment Impact",
              "value": "Increased R&D expenditures expected, with potential for sustained losses from operations."
            },
            {
              "key": "Market Acceptance",
              "value": "Future revenues depend on effective market acceptance and reimbursement of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risk Factors Related to Gene Therapy and Regulatory Approval",
          "data": [
            {
              "key": "Potential risks of gene therapy",
              "value": "Serious side effects such as uncontrolled viral infections and cancer."
            },
            {
              "key": "Regulatory approval risks",
              "value": "Delays or failures in obtaining regulatory approval may decrease revenue potential."
            },
            {
              "key": "Public perception risks",
              "value": "Negative public attitude towards gene therapy technology could affect acceptance."
            },
            {
              "key": "Clinical trial concerns",
              "value": "Results from ongoing trials may not predict future success, altering development plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 56,
          "title": "Regulatory Approval and Market Limitations for COVAXIN",
          "data": [
            {
              "key": "Vaccine Candidate",
              "value": "COVAXIN"
            },
            {
              "key": "Current Development Challenges",
              "value": "Potentially less effective against new variants and unacceptable safety profile could negatively impact development in the US."
            },
            {
              "key": "Regulatory Bodies",
              "value": "FDA for US, Health Canada for Canada, COFEPRIS for Mexico"
            },
            {
              "key": "Current Status in Canada",
              "value": "Amendment to Covaxin Agreement with rights to develop and commercialize in Canada."
            },
            {
              "key": "Approval Status in Canada",
              "value": "Health Canada marketing approval required."
            },
            {
              "key": "Canada's Approval Process",
              "value": "Evaluate under Interim Order for expedited approval."
            },
            {
              "key": "Withdrawal of NDS",
              "value": "Withdrew NDS based on discussions with Health Canada."
            },
            {
              "key": "Clinical Trials Sufficiency",
              "value": "Clinical trials in India and US may not support marketing approval in Canada or Mexico."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "Costly difficulties may arise in obtaining approvals, with no guaranteed success."
            },
            {
              "key": "EUA Status in Mexico",
              "value": "COVAXIN authorized for emergency use for adults."
            },
            {
              "key": "Pediatric EUA Discussions",
              "value": "In discussions regarding EUA for pediatric use."
            },
            {
              "key": "Impact of New Variants",
              "value": "Emerging SARS-CoV-2 variants could reduce vaccines' effectiveness."
            },
            {
              "key": "COVID-19 Pandemic Impact",
              "value": "Continued pandemic may disrupt business operations and financial positions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "Impact of COVID-19 on Supply Chain and Regulatory Processes",
          "data": [
            {
              "key": "Summary",
              "value": "The COVID-19 pandemic is causing disruptions in global supply chains affecting clinical trials and product approvals."
            },
            {
              "key": "Key Risks",
              "value": "Delays in obtaining regulatory approvals, increased costs of capital, potential economic slowdown."
            },
            {
              "key": "Regulatory Risks",
              "value": "Regulatory approval processes are lengthy and unpredictable, which may affect commercialization."
            },
            {
              "key": "Market Impact",
              "value": "Failure to receive approvals can significantly harm financial position and adversely impact stock price."
            },
            {
              "key": "Clinical Trial Risks",
              "value": "Unforeseen events during clinical trials may delay or prevent marketing approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risk Factors Related to Clinical Trials and Regulatory Approval",
          "data": [
            {
              "key": "Challenges in obtaining marketing approval",
              "value": "Changes in marketing approval policies or regulations may render data insufficient for marketing approval."
            },
            {
              "key": "Cost of clinical trials",
              "value": "Clinical trial costs may exceed estimates, potentially impacting funding."
            },
            {
              "key": "Quality of clinical trial materials",
              "value": "Supply or quality of product candidates may be inadequate for trials."
            },
            {
              "key": "Clinical trial delays",
              "value": "Delays may occur in adding investigators or withdrawal of clinical sites."
            },
            {
              "key": "Patient eligibility misrepresentation",
              "value": "Patients may misrepresent eligibility, complicating study protocols."
            },
            {
              "key": "Regulatory authority disagreements",
              "value": "FDA or foreign authorities may disagree with study design or interpretation of data."
            },
            {
              "key": "Data acceptance risks",
              "value": "Regulatory authorities may not accept data from foreign trial sites."
            },
            {
              "key": "Manufacturing process scrutiny",
              "value": "Regulatory bodies may find fault with manufacturing processes impacting approval."
            },
            {
              "key": "Insufficient trial data",
              "value": "Clinical trial data may fail to meet regulatory satisfaction for approvals."
            },
            {
              "key": "Decision timelines",
              "value": "Regulatory decisions may take longer than anticipated, impacting commercialization."
            },
            {
              "key": "Competition risks",
              "value": "Delays may allow competitors to market prior to approval."
            },
            {
              "key": "Administrative sanctions",
              "value": "Failure to comply with regulations may lead to sanctions and operational restrictions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Risks Related to Clinical Trials and Product Candidates",
          "data": [
            {
              "key": "Perceived Risks",
              "value": "Risks and benefits of the product candidate including competition in recruiting patients and obtaining informed consent."
            },
            {
              "key": "Enrollment Difficulty",
              "value": "Challenges in enrolling sufficient eligible patients may lead to significant delays."
            },
            {
              "key": "Impact of Withdrawals",
              "value": "High dropout rates could compromise study quality and data integrity."
            },
            {
              "key": "Variability in Results",
              "value": "Preliminary results not necessarily indicative of outcomes in later trials."
            },
            {
              "key": "Resource Allocation",
              "value": "Limited resources may lead to missed opportunities with other product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 67,
          "title": "International Operations Risks",
          "data": [
            {
              "key": "Intellectual Property Risks",
              "value": "Challenges enforcing contractual and intellectual property rights in foreign countries."
            },
            {
              "key": "Patent Approval Challenges",
              "value": "Need for additional patent approvals and licenses, facing claims of patent infringement."
            },
            {
              "key": "Tariff and Regulatory Changes",
              "value": "Unexpected changes in tariffs, trade barriers, and regulatory requirements."
            },
            {
              "key": "Economic Weakness",
              "value": "Economic weaknesses, inflation, or political instability affecting foreign markets."
            },
            {
              "key": "Compliance Challenges",
              "value": "Compliance with tax, employment, labor laws for employees abroad."
            },
            {
              "key": "Currency Fluctuation Risks",
              "value": "Foreign currency fluctuations affecting operating expenses and revenues."
            },
            {
              "key": "Staffing Difficulties",
              "value": "Issues in staffing and managing operations abroad."
            },
            {
              "key": "Labor Unrest Risks",
              "value": "Workforce uncertainty in countries with more common labor unrest."
            },
            {
              "key": "Liability Under Foreign Laws",
              "value": "Potential liability under the FCPA, Bribery Act, or similar regulations."
            },
            {
              "key": "Production Shortages",
              "value": "Production shortages due to events affecting raw material supplies."
            },
            {
              "key": "Business Interruptions",
              "value": "Interruptions from geopolitical actions, natural disasters, and pandemics."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 68,
          "title": "Competitive Landscape in Biotechnology and Pharmaceuticals",
          "data": [
            {
              "key": "Key Competitors",
              "value": "Major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, government agencies, and other research organizations."
            },
            {
              "key": "Competitive Products",
              "value": "Gene therapies for ophthalmic indications, neoCart product candidate, COVAXIN, novel inhaled mucosal vaccine platform."
            },
            {
              "key": "Current Market Approval",
              "value": "Luxturna is the only gene therapy approved to treat IRDs in the U.S."
            },
            {
              "key": "Notable Competitors",
              "value": "Applied Genetic Technologies Corporation, Astellas Pharma Inc., MeiraGTx Holdings plc, Novartis AG, Pfizer/BioNTech, Moderna, AstraZeneca."
            },
            {
              "key": "Market Risks",
              "value": "If competitors develop and commercialize safer, more effective products, our commercial opportunities could be reduced."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 70,
          "title": "Risk Factors Related to Product Market Opportunities and Reimbursement",
          "data": [
            {
              "key": "Market Opportunities",
              "value": "Potential market opportunities for product candidates could be smaller than estimated."
            },
            {
              "key": "Reimbursement Challenges",
              "value": "Third-party payers may set reimbursement levels too low for profitability."
            },
            {
              "key": "Approval Dependencies",
              "value": "Successful commercialization is dependent on coverage and adequate reimbursement."
            },
            {
              "key": "Cost-Effectiveness Requirement",
              "value": "Time-consuming and costly processes may be required for coverage approval."
            },
            {
              "key": "Denial of Reimbursement",
              "value": "Third-party payors may deny reimbursement for procedures and products deemed experimental or unapproved."
            },
            {
              "key": "Price Controls",
              "value": "Third-party payors may impose price controls and conditions for coverage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 73,
          "title": "Supply Chain and Manufacturing Risks for COVAXIN",
          "data": [
            {
              "key": "Dependency on suppliers",
              "value": "We continue to depend on Bharat Biotech as a single-source supplier."
            },
            {
              "key": "Impact of manufacturing issues",
              "value": "Manufacturing challenges may jeopardize commercial supply."
            },
            {
              "key": "Regulatory compliance",
              "value": "Compliance with FDA regulations is crucial."
            },
            {
              "key": "Potential delays",
              "value": "Third-party manufacturers may fail to meet specifications or timelines."
            },
            {
              "key": "Quality assurance",
              "value": "Production quality and regulatory compliance are central to success."
            },
            {
              "key": "GMP compliance",
              "value": "Manufacturers must comply with GMP requirements enforced by FDA."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 75,
          "title": "Supply Chain Risks and Collaboration Challenges",
          "data": [
            {
              "key": "Description",
              "value": "Challenges in obtaining suitable alternative manufacturers for product candidates and potential delays in meeting commercial demand or advancing clinical trials."
            },
            {
              "key": "Potential Issues",
              "value": "Costs related to establishing new manufacturing arrangements, potential FDA compliance issues, and limited third-party facility availability due to various disasters."
            },
            {
              "key": "Collaboration Efforts",
              "value": "Ongoing agreements with CanSinoBIO and Bharat Biotech, alongside considerations for future partnerships with pharmaceutical companies."
            },
            {
              "key": "Risks of Collaboration",
              "value": "Disagreement among collaborators may cause delays and could lead to termination of agreements affecting business operations."
            },
            {
              "key": "External Factors",
              "value": "Collaborators may withdraw from development or commercialization based on various strategic reasons or changes in focus."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 81,
          "title": "Patent Rights Uncertainty",
          "data": [
            {
              "key": "Primary Risks",
              "value": "Uncertainty surrounding the issuance, scope, validity, enforceability, and commercial value of patent rights."
            },
            {
              "key": "Legal Challenges",
              "value": "Patent applications may be challenged in courts or patent offices, leading to potential loss of exclusivity."
            },
            {
              "key": "Regulatory Changes",
              "value": "Changes in patent laws may impact the value and scope of patent protections."
            },
            {
              "key": "Competitors",
              "value": "Competitors may develop alternative products that circumvent existing patents."
            },
            {
              "key": "Patent Reforms",
              "value": "Potential impacts of the Leahy-Smith America Invents Act on patent application prosecution and litigation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 96,
          "title": "Management's Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "company",
              "value": "biotechnology company"
            },
            {
              "key": "focus",
              "value": "discovering, developing, and commercializing novel gene and cell therapies and vaccines"
            },
            {
              "key": "risks",
              "value": "risks, uncertainties, and assumptions about future outcomes"
            },
            {
              "key": "products",
              "value": "Modifier Gene Therapy Platform, Regenerative Medicine Cell Therapy Platform, Vaccines, Novel Biologic Therapy for Retinal Diseases"
            },
            {
              "key": "orphan_drug_designation",
              "value": "OCU400 received Orphan Drug Designation for NR2E3-related RP and LCA"
            },
            {
              "key": "clinical_trial",
              "value": "Phase 1/2 clinical trial for OCU400 treating NR2E3 and RHO-related RP and CEP290-related LCA"
            },
            {
              "key": "target_diseases",
              "value": "retinal diseases such as RP, LCA, DME, DR, and AMD"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 1,
          "title": "Table of Contents and Company Information",
          "data": [
            {
              "key": "Company Name",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Type of Report",
              "value": "Annual Report"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "State of Incorporation",
              "value": "Delaware"
            },
            {
              "key": "Company Address",
              "value": "11 Great Valley Parkway, Malvern, Pennsylvania 19355"
            },
            {
              "key": "Telephone Number",
              "value": "(484) 328-4701"
            },
            {
              "key": "Securities Registered",
              "value": "Trading information with no entries available"
            },
            {
              "key": "Type of Issuer",
              "value": "Smaller reporting company and Emerging growth company"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Disclosure Regarding Forward-Looking Statements",
          "data": [
            {
              "key": "Statement Type",
              "value": "Forward-looking statements"
            },
            {
              "key": "Key Areas of Uncertainty",
              "value": "Future financial position, revenues, projected costs"
            },
            {
              "key": "Clinical Trials Mentioned",
              "value": "Phase 1/2 clinical trial, Phase 3 clinical trial, pediatric Phase 1/2 clinical trial"
            },
            {
              "key": "Collaboration Partner",
              "value": "Bharat Biotech International Limited"
            },
            {
              "key": "Vaccine Candidates",
              "value": "OCU400, BBV152 (COVAXIN)"
            },
            {
              "key": "Risks Identified",
              "value": "Uncertainty in clinical development, financial requirements, regulatory approvals, market acceptance"
            },
            {
              "key": "Regulatory Body",
              "value": "U.S. Food and Drug Administration (FDA)"
            },
            {
              "key": "Outcome Uncertainties",
              "value": "Clinical trial delays, pricing and reimbursement issues, patent protection"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 28,
          "title": "Purpose Agreement Amendment and Covaxin Agreement",
          "data": [
            {
              "key": "Amendment Date",
              "value": "June 2012"
            },
            {
              "key": "Exclusive Rights Grantor",
              "value": "Purpose"
            },
            {
              "key": "Exclusive Rights Grantee",
              "value": "Histogenics"
            },
            {
              "key": "Development Rights",
              "value": "NeoCart in Japan"
            },
            {
              "key": "Obligation to Pay",
              "value": "up to $10.0 million"
            },
            {
              "key": "Royalty Payment",
              "value": "low single digits on net sales in Japan"
            },
            {
              "key": "Covaxin Agreement Execution Date",
              "value": "February 2021"
            },
            {
              "key": "Covaxin Agreement Amendment Date",
              "value": "June 2021"
            },
            {
              "key": "Upfront Payment for Canadian Rights",
              "value": "$15.0 million"
            },
            {
              "key": "Payment Post First Commercial Sale",
              "value": "$10.0 million"
            },
            {
              "key": "Profit Share",
              "value": "45% for Ocugen, balance for Bharat Biotech"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 30,
          "title": "INTELLECTUAL PROPERTY",
          "data": [
            {
              "key": "Patent Portfolio",
              "value": "24 issued patents in the US, 63 issued or registered patents overseas, 9 pending in the US, and 14 pending overseas."
            },
            {
              "key": "Exclusive Rights",
              "value": "Two issued US patents and one pending US application related to OCU400, and additional patents for OCU410, NeoCart, OCU500, OCU520, and OCU200."
            },
            {
              "key": "Expiration Dates",
              "value": "Patents expire between 2024 and 2038."
            },
            {
              "key": "Covaxin Agreement",
              "value": "Obtained exclusive rights to develop, manufacture, and commercialize COVAXIN."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 36,
          "title": "FDA Regulatory Review and Approval Process",
          "data": [
            {
              "key": "NDA/BLA Approval",
              "value": "First applicant to receive FDA approval for a particular active moiety entitled to seven-year exclusive marketing period."
            },
            {
              "key": "Exclusivity Period",
              "value": "During the seven-year exclusivity, FDA may not approve other applications for the same drug for the same disease."
            },
            {
              "key": "Patent Term Restoration",
              "value": "Approved drug products may be eligible for patent term restoration for a maximum of five years."
            },
            {
              "key": "Expedited Review Programs",
              "value": "FDA provides programs to expedite development for serious conditions, including fast track and breakthrough therapy designations."
            },
            {
              "key": "Priority Review",
              "value": "Goals to review an application within six months instead of ten."
            },
            {
              "key": "Accelerated Approval",
              "value": "Approval based on surrogate or clinical endpoints expected to predict clinical benefit."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Rigorous compliance, including Phase 4 trials, is required to confirm clinical benefit."
            },
            {
              "key": "Breakthrough Therapy Definition",
              "value": "Product candidate intended to treat a serious or life-threatening disease."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 51,
          "title": "Future Capital Requirements",
          "data": [
            {
              "key": "Key Factors for Capital Requirements",
              "value": "The initiation, progress, timing, costs, and results of clinical trials for our product candidates."
            },
            {
              "key": "Regulatory Approval Costs",
              "value": "The outcome, timing, and cost of the regulatory approval process for our product candidates."
            },
            {
              "key": "Manufacturing and Commercialization Costs",
              "value": "The costs of manufacturing and commercialization."
            },
            {
              "key": "International Business Costs",
              "value": "The costs related to doing business internationally."
            },
            {
              "key": "Intellectual Property Costs",
              "value": "The cost of filing, prosecuting, defending, and enforcing patent claims."
            },
            {
              "key": "Infrastructure Expansion Costs",
              "value": "The costs of expanding infrastructure to support development, commercialization, and business efforts."
            },
            {
              "key": "Recruitment Costs",
              "value": "The costs involved in recruiting and retaining skilled personnel."
            },
            {
              "key": "Licensing and Acquisition Factors",
              "value": "The extent to which we in-license or acquire other products or technologies."
            },
            {
              "key": "Out-Licensing Factors",
              "value": "The extent to which we out-license our product candidates."
            },
            {
              "key": "Geopolitical and Macroeconomic Impact",
              "value": "The impact of geopolitical turmoil and macroeconomic conditions."
            },
            {
              "key": "Financing Availability",
              "value": "Adequate additional financing may not be available."
            },
            {
              "key": "Capital Raising through Strategic Collaborations",
              "value": "Expect to raise additional capital through public/private placements, licensing, etc."
            },
            {
              "key": "Government Funding for Vaccine Development",
              "value": "Anticipated government funding for vaccine candidate development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 53,
          "title": "Risk Factors Related to Tax Liabilities and Product Development",
          "data": [
            {
              "key": "Tax Legislation Change Impact",
              "value": "Adverse effect on financial condition, results of operations, and cash flows."
            },
            {
              "key": "Regulatory Approval Uncertainty",
              "value": "Uncertainty regarding completion and commercialization of product candidates."
            },
            {
              "key": "Dependence on Product Candidates",
              "value": "Business operations heavily depend on successful product candidate development."
            },
            {
              "key": "No Revenue Generation",
              "value": "Currently no products are commercially distributed, impacting revenue generation."
            },
            {
              "key": "Potential Risks in Development",
              "value": "Susceptibility to unexpected events during product development."
            },
            {
              "key": "Impact of Regulatory Filings",
              "value": "Results or timing of regulatory activities may affect market price of common stock."
            },
            {
              "key": "Approval for Marketing",
              "value": "Regulatory approval required for successful marketing of product candidates."
            },
            {
              "key": "Clinical Trial Success Factors",
              "value": "Successful results required to obtain marketing approval."
            },
            {
              "key": "Workforce Needs",
              "value": "Need to maintain experienced workforce for continued development."
            },
            {
              "key": "Market Launch Plans",
              "value": "Plans needed to promote product candidates upon approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 59,
          "title": "Regulatory and Manufacturing Challenges for Vaccine Development",
          "data": [
            {
              "key": "Regulatory Approval Risks",
              "value": "Challenges in obtaining regulatory approval due to restrictions, safety warnings, and additional trials."
            },
            {
              "key": "Manufacturing Experience",
              "value": "Limited experience in manufacturing, distribution, or commercialization of vaccine candidates."
            },
            {
              "key": "Supply Chain Challenges",
              "value": "Potential difficulties in sourcing raw materials and establishing a supply chain."
            },
            {
              "key": "Product Liability Risks",
              "value": "Increased risk of product liability claims due to biologic nature of products."
            },
            {
              "key": "Government Restrictions",
              "value": "Possible imposition of restrictions on biologically derived substances manufactured in or imported from China."
            },
            {
              "key": "Competitor Monitoring",
              "value": "Need to monitor competitors' performance and compliance with regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 61,
          "title": "Regulatory Challenges and Delays in Clinical Trials",
          "data": [
            {
              "key": "Undesirable Side Effects",
              "value": "Could cause interruptions, delays, or halts in clinical trials."
            },
            {
              "key": "Regulatory Approval Delays",
              "value": "FDA may order to cease development or request additional data."
            },
            {
              "key": "Patient Recruitment Issues",
              "value": "Difficulty in recruiting patients may lead to trial delays."
            },
            {
              "key": "Impact of Adverse Events",
              "value": "May affect drug approval and commercial adoption."
            },
            {
              "key": "Financial Consequences",
              "value": "Delays or failures in trials could harm financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 63,
          "title": "Regulatory Approval Process and Implications for International Marketing",
          "data": [
            {
              "key": "Key Issues",
              "value": "Potential challenges in product approval and commercialization in international markets."
            },
            {
              "key": "FDA Acceptance",
              "value": "Regulatory acceptance of clinical trial data conducted outside the U.S. is uncertain."
            },
            {
              "key": "Marketing Approval",
              "value": "Requires separate approval in each jurisdiction with varying requirements."
            },
            {
              "key": "Risks of Non-approval",
              "value": "Non-approval in one jurisdiction may hinder approval in others."
            },
            {
              "key": "Compliance Risks",
              "value": "Potential fines and penalties for off-label promotions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 82,
          "title": "Patent Term Extension Risks and Implications",
          "data": [
            {
              "key": "Patent Term Extension",
              "value": "Discussion on the implications of not being able to obtain patent term extensions under the Hatch-Waxman Act."
            },
            {
              "key": "Regulatory Scrutiny",
              "value": "Increasing uncertainties and costs associated with patent maintenance and enforcement due to potential challenges."
            },
            {
              "key": "Litigation Risks",
              "value": "Involvement in lawsuits to protect patents can be expensive and time-consuming."
            },
            {
              "key": "Potential Outcomes",
              "value": "Risk of patents being invalidated or narrow interpretation in litigation."
            },
            {
              "key": "Third-Party Interference",
              "value": "Adverse events from third-party challenges could diminish patent rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 87,
          "title": "Risks Related to Our Common Stock",
          "data": [
            {
              "key": "Trade Secrets",
              "value": "If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed."
            },
            {
              "key": "Dividends",
              "value": "We do not currently intend to pay dividends on our common stock and anticipate retaining future earnings."
            },
            {
              "key": "Impact of Selling Shares",
              "value": "Sales of a substantial number of common stock by our stockholders in the public market could cause our stock price to fall."
            },
            {
              "key": "Takeover Provisions",
              "value": "Provisions in our charter documents could discourage favorable takeovers and lead to management entrenchment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 90,
          "title": "Growth Management and Regulatory Compliance",
          "data": [
            {
              "key": "anticipated growth",
              "value": "significant"
            },
            {
              "key": "impact of regulatory compliance on operations",
              "value": "increased costs, time-consuming, and costly"
            },
            {
              "key": "significant legislative requirements for public companies",
              "value": "Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform"
            },
            {
              "key": "effects of compliance on management",
              "value": "diverts attention from other business concerns"
            },
            {
              "key": "potential additional costs and regulations",
              "value": "continuous revisions and new compliance obligations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 95,
          "title": "Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities",
          "data": [
            {
              "key": "market_information",
              "value": "Our common stock is traded on the Nasdaq Capital Market under the symbol 'OCGN.'"
            },
            {
              "key": "holders",
              "value": "As of February 21, 2023, we had 226.4 million shares of common stock outstanding held by approximately 22 stockholders of record."
            },
            {
              "key": "dividends",
              "value": "We have not declared or paid any cash dividends on our common stock and do not anticipate declaring or paying any cash dividends for the foreseeable future."
            },
            {
              "key": "issuer_purchases",
              "value": "During the quarter ended December 31, 2022, we did not repurchase any shares of our common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 99,
          "title": "Operating expenses",
          "data": [
            {
              "key": "Research and development (2022)",
              "value": "49,757 $"
            },
            {
              "key": "Research and development (2021)",
              "value": "35,108"
            },
            {
              "key": "Change in R&D expenses",
              "value": "14,649"
            },
            {
              "key": "General and administrative (2022)",
              "value": "35,111"
            },
            {
              "key": "General and administrative (2021)",
              "value": "22,920"
            },
            {
              "key": "Change in G&A expenses",
              "value": "12,191"
            },
            {
              "key": "Total operating expenses (2022)",
              "value": "84,868"
            },
            {
              "key": "Total operating expenses (2021)",
              "value": "58,028"
            },
            {
              "key": "Change in Total operating expenses",
              "value": "26,840"
            },
            {
              "key": "Net loss (2022)",
              "value": "(81,351) $"
            },
            {
              "key": "Net loss (2021)",
              "value": "(58,365)"
            },
            {
              "key": "Change in Net loss",
              "value": "(22,986)"
            },
            {
              "key": "Other income (2022)",
              "value": "3,517"
            },
            {
              "key": "Other income (2021)",
              "value": "(389)"
            },
            {
              "key": "Change in Other income",
              "value": "3,906"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 105,
          "title": "Controls and Procedures",
          "data": [
            {
              "key": "Disclosure Controls and Procedures",
              "value": "Effective"
            },
            {
              "key": "Internal Control Over Financial Reporting",
              "value": "Effective as of December 31, 2022"
            },
            {
              "key": "Management's Responsibility",
              "value": "Responsible for adequate internal control over financial reporting"
            },
            {
              "key": "Risk of Misstatements",
              "value": "May not prevent or detect misstatements"
            },
            {
              "key": "Evaluation Criteria",
              "value": "Based on COSO 2013 framework"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 108,
          "title": "Table of Contents Part IV Item 15",
          "data": [
            {
              "key": "Financial Statements",
              "value": "See 'Index to Consolidated Financial Statements' beginning on page F-1 of this report."
            },
            {
              "key": "Financial Statement Schedules",
              "value": "Not applicable."
            },
            {
              "key": "Exhibits",
              "value": "The exhibits required to be filed as part of this Annual Report on Form 10-K are listed in the Exhibit Index attached hereto and are incorporated herein by reference."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 109,
          "title": "Corporate Governance Document Index",
          "data": [
            {
              "key": "reference_number",
              "value": "3.1"
            },
            {
              "key": "description",
              "value": "Sixth Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K as filed on December 8, 2014, and incorporated herein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.2"
            },
            {
              "key": "description",
              "value": "Amendment to Sixth Amended and Restated Certificate of related to the Reverse Stock and the Authorized Incorporation Split Share Increase (filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K as filed October 1, 2019, and incorporated herein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.3"
            },
            {
              "key": "description",
              "value": "Amendment to Sixth Amended and Restated Certificate of Incorporation related to the Name Change (filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K as filed on October 1, 2019, and incorporated herein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.4"
            },
            {
              "key": "description",
              "value": "Amendment to Sixth Amended and Restated Certificate of Incorporation related to the Increase in Authorized Shares of Common Stock (filed as Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q as filed on May 7, 2021, and incorporated herein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.5"
            },
            {
              "key": "description",
              "value": "Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Histogenics Corporation (filed as Exhibit 3.3 to the Registrant's Current Report on Form 8-K as filed on September 16, 2016, and incorporated erein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.6"
            },
            {
              "key": "description",
              "value": "Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock of Ocugen, Inc. (filed as Exhibit 3.5 to the Registrant's Annual Report on Form 10-K filed on March 19, 2021 and incorporated herein by reference)"
            },
            {
              "key": "reference_number",
              "value": "3.7"
            },
            {
              "key": "description",
              "value": "Amended and Restated Bylaws (filed as Exhibit 3.3 to the Registrant's Current Report on Form 8-K as filed on October 1, 2019, and incorporated herein by reference)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 121,
          "title": "Nature of Business and Clinical Developments",
          "data": [
            {
              "key": "Company Name",
              "value": "Ocugen, Inc."
            },
            {
              "key": "Focus Area",
              "value": "Biotechnology and gene therapy"
            },
            {
              "key": "Key Products",
              "value": "OCU400, NeoCart"
            },
            {
              "key": "Clinical Trial Phase for OCU400",
              "value": "Phase 1/2"
            },
            {
              "key": "Intended Initiation of Pediatric Trial",
              "value": "Q2 2023"
            },
            {
              "key": "Intended Initiation of Phase 3 Trial for OCU400",
              "value": "End of 2023"
            },
            {
              "key": "NeoCart Clinical Trial Phase",
              "value": "Phase 3"
            },
            {
              "key": "Intended Initiation of NeoCart Phase 3 Trial",
              "value": "H1 2024"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 127,
          "title": "Guidance on Accounting Standards",
          "data": [
            {
              "key": "Standard Issued",
              "value": "ASU No. 2021-10"
            },
            {
              "key": "Topic",
              "value": "Government Assistance (Topic 832)"
            },
            {
              "key": "Purpose",
              "value": "Increases transparency of government transactions."
            },
            {
              "key": "Impact",
              "value": "Aims to reduce diversity in accounting practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 133,
          "title": "Property and Equipment Breakdown",
          "data": [
            {
              "key": "Furniture and fixtures 2022",
              "value": "337"
            },
            {
              "key": "Furniture and fixtures 2021",
              "value": "284"
            },
            {
              "key": "Machinery and equipment 2022",
              "value": "1685"
            },
            {
              "key": "Machinery and equipment 2021",
              "value": "855"
            },
            {
              "key": "Leasehold improvements 2022",
              "value": "1603"
            },
            {
              "key": "Leasehold improvements 2021",
              "value": "167"
            },
            {
              "key": "Construction in progress 2022",
              "value": "3049"
            },
            {
              "key": "Construction in progress 2021",
              "value": "232"
            },
            {
              "key": "Total property and equipment 2022",
              "value": "6674"
            },
            {
              "key": "Total property and equipment 2021",
              "value": "1538"
            },
            {
              "key": "Less: accumulated depreciation 2022",
              "value": "-621"
            },
            {
              "key": "Less: accumulated depreciation 2021",
              "value": "-374"
            },
            {
              "key": "Total property and equipment, net 2022",
              "value": "6053"
            },
            {
              "key": "Total property and equipment, net 2021",
              "value": "1164"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 133,
          "title": "Operating Leases",
          "data": [
            {
              "key": "Operating lease cost 2022",
              "value": "714"
            },
            {
              "key": "Operating lease cost 2021",
              "value": "360"
            },
            {
              "key": "Variable lease cost 2022",
              "value": "158"
            },
            {
              "key": "Variable lease cost 2021",
              "value": "105"
            },
            {
              "key": "Total lease cost 2022",
              "value": "932"
            },
            {
              "key": "Total lease cost 2021",
              "value": "465"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 133,
          "title": "Right-of-use Assets and Lease Obligations Comparison",
          "data": [
            {
              "key": "Right-of-use assets, net 2022",
              "value": "3910"
            },
            {
              "key": "Right-of-use assets, net 2021",
              "value": "1587"
            },
            {
              "key": "Current lease obligations 2022",
              "value": "498"
            },
            {
              "key": "Current lease obligations 2021",
              "value": "363"
            },
            {
              "key": "Non-current lease obligations 2022",
              "value": "3587"
            },
            {
              "key": "Non-current lease obligations 2021",
              "value": "1231"
            },
            {
              "key": "Total lease liabilities 2022",
              "value": "4085"
            },
            {
              "key": "Total lease liabilities 2021",
              "value": "1594"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 133,
          "title": "Weighted-average Remaining Lease Terms Comparison",
          "data": [
            {
              "key": "Weighted-average remaining lease terms (years) 2022",
              "value": "6.3"
            },
            {
              "key": "Weighted-average remaining lease terms (years) 2021",
              "value": "5.3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 164,
          "title": "Change of Control and Good Reason Definitions",
          "data": [
            {
              "key": "Definition of Change of Control",
              "value": "Means the closing of the sale, transfer or disposition of all or substantially all of the Companyâs assets, or acquisition of more than 50% voting power of the securities."
            },
            {
              "key": "Definition of Good Reason",
              "value": "Occurrence of specified events without prior written consent of Employee, allowing Employee to resign."
            },
            {
              "key": "Disability",
              "value": "Employeeâs inability to perform essential duties for six consecutive months or 180 business days in twelve months due to impairment."
            },
            {
              "key": "Circumstances for Good Reason",
              "value": "Includes reduction in compensation, termination of benefits, material reduction in job title."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 32,
          "title": "Clinical Trial Regulations",
          "data": [
            {
              "key": "Clinical Trial Oversight",
              "value": "The IRB must oversee the clinical trial during its conduct."
            },
            {
              "key": "Reporting Responsibilities",
              "value": "Progress reports detailing results must be submitted annually to the FDA and IRB."
            },
            {
              "key": "Safety Reporting",
              "value": "IND safety reports for serious adverse events must be submitted promptly."
            },
            {
              "key": "FDA Authority",
              "value": "FDA may order discontinuation of trials if not in accordance with requirements."
            },
            {
              "key": "Clinical Hold",
              "value": "FDA issues a hold for non-compliance or unacceptable risk."
            },
            {
              "key": "Expanded Access Policy",
              "value": "Sponsors must have a publicly available policy for expanded access requests."
            },
            {
              "key": "GMP Compliance",
              "value": "Manufacture of investigational products must meet current GMP requirements."
            },
            {
              "key": "FDA Regulatory Requirements",
              "value": "Investigational drugs and biologics are subject to FDA and other regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 35,
          "title": "FDA Regulatory Compliance and Orphan Drug Act Overview",
          "data": [
            {
              "key": "FDA Compliance Requirements",
              "value": "Manufacturers must comply with current GMP regulations and practices."
            },
            {
              "key": "Material Changes in Manufacturing",
              "value": "Requires additional regulatory review and approval."
            },
            {
              "key": "Consequences of Non-compliance",
              "value": "Potential for fines or penalties, production restrictions, and product recalls."
            },
            {
              "key": "Emergency Use Authorization (EUA) Conditions",
              "value": "Compliance with labeling, reporting obligations, and advertising restrictions."
            },
            {
              "key": "Pediatric Exclusivity Conditions",
              "value": "FDA must request pediatric studies and applicant must agree to perform them."
            },
            {
              "key": "Orphan Drug Designation (ODD) Criteria",
              "value": "Applies to products for rare diseases affecting less than 0.2 million individuals."
            },
            {
              "key": "Financial Incentives for ODD",
              "value": "Includes grant funding, tax advantages, and user-fee waivers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 37,
          "title": "Regulatory Framework for Drug Development and Approval",
          "data": [
            {
              "key": "Preliminary Evidence",
              "value": "Preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies."
            },
            {
              "key": "Breakthrough Therapies",
              "value": "Products designated as breakthrough therapies are eligible for intensive guidance on an efficient development program."
            },
            {
              "key": "RMAT Designation",
              "value": "A regenerative medicine advanced therapy is eligible for RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life threatening disease."
            },
            {
              "key": "Post-approval Requirements",
              "value": "Products manufactured or distributed pursuant to FDA approvals are subject to extensive and continuing regulation by the FDA."
            },
            {
              "key": "Compliance and Inspections",
              "value": "Manufacturers are required to register with the FDA and state agencies and are subject to inspections for compliance."
            },
            {
              "key": "Marketing Regulations",
              "value": "The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market."
            },
            {
              "key": "Off-label Promotion",
              "value": "Companies are prohibited from promoting products for unapproved indications."
            },
            {
              "key": "Liability for Non-compliance",
              "value": "A company that improperly promotes off-label uses may face significant liability including criminal and civil penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 38,
          "title": "Regulations on Biotechnological Products and FDA Control",
          "data": [
            {
              "key": "Program Name",
              "value": "Medicaid Drug Rebate Program (MDRP)"
            },
            {
              "key": "Obligations on Sponsors",
              "value": "Product tracking, labeling, record-keeping."
            },
            {
              "key": "Legislation",
              "value": "Drug Quality and Security Act"
            },
            {
              "key": "Responsibilities of Manufacturers",
              "value": "Investigations and notifications about counterfeit or unsafe products."
            },
            {
              "key": "Regulatory Actions",
              "value": "License suspensions, product recalls, fines, FDA debarment, etc."
            },
            {
              "key": "Additional Authority",
              "value": "FDA power to suspend licenses for public health dangers."
            },
            {
              "key": "Biologics Manufacturing Controls",
              "value": "Regulatory standards for safety, purity, potency, and effectiveness."
            },
            {
              "key": "Gene Therapy",
              "value": "Subject to NIH guidelines and FDA monitoring."
            },
            {
              "key": "Clinical Trials",
              "value": "Standards for research involving genetic material."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 39,
          "title": "Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations",
          "data": [
            {
              "key": "Regulatory Authorities",
              "value": "FDA, Department of Justice, Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS), Health Resources and Services Administration, Department of Veterans Affairs, Department of Defense, state and local governments."
            },
            {
              "key": "Compliance Requirements",
              "value": "Healthcare laws including anti-kickback and false claims laws and data privacy and security regulations."
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits any remuneration to induce referrals for federal healthcare covered business."
            },
            {
              "key": "Patient Protection and Affordable Care Act (ACA) Changes",
              "value": "Modified intent requirement for violations of the Anti-Kickback Statute."
            },
            {
              "key": "False Claims Act (FCA) Violations",
              "value": "Prohibits knowingly presenting false claims to the federal government."
            },
            {
              "key": "Qui Tam Actions",
              "value": "Private individuals can bring actions on behalf of the government."
            },
            {
              "key": "Consequences of FCA Violations",
              "value": "Treble damages, civil penalties, and exclusion from federal healthcare programs."
            },
            {
              "key": "Recent Trends in FCA Lawsuits",
              "value": "Significant increase in lawsuits against biotechnological companies since 2004, with high settlements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 40,
          "title": "Regulatory and Compliance Risks",
          "data": [
            {
              "key": "False Claims Act (FCA)",
              "value": "The government may further prosecute conduct constituting a false claim under the criminal FCA."
            },
            {
              "key": "Civil Monetary Penalties",
              "value": "Imposes fines against anyone knowingly presenting false claims to a federal healthcare program."
            },
            {
              "key": "Medicaid and Medicare Reimbursement",
              "value": "Payment or reimbursement requires submitting certified pricing information to CMS."
            },
            {
              "key": "Medicaid Drug Rebate",
              "value": "Requires labelers to calculate and report pricing information for Medicaid rebate payments."
            },
            {
              "key": "Veterans Health Care Act (VHCA)",
              "value": "Requires specific pricing calculations for federal agencies to determine maximum allowable prices."
            },
            {
              "key": "TRICARE Program",
              "value": "Labelers must provide discounts on therapeutics dispensed by retail pharmacies when paid by the TRICARE Program."
            },
            {
              "key": "340B Program",
              "value": "Mandates different mandatory discounts to certain safety net hospitals."
            },
            {
              "key": "HIPAA Criminal Statutes",
              "value": "Prohibits schemes to defraud healthcare benefit programs; amended by ACA."
            },
            {
              "key": "Physician Payments Sunshine Act",
              "value": "Creates new requirements for reporting payments and transfers of value to healthcare providers."
            },
            {
              "key": "HITECH Act",
              "value": "Strengthens HIPAA security and privacy standards for business associates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 41,
          "title": "Compliance with HIPAA and related state laws",
          "data": [
            {
              "key": "Topic",
              "value": "Overview of compliance with federal and state laws regarding health information."
            },
            {
              "key": "Implications",
              "value": "Penalties for non-compliance include significant monetary penalties and operational restrictions."
            },
            {
              "key": "Legislation",
              "value": "States are enacting laws for drug price transparency and marketing practices."
            },
            {
              "key": "Regulatory Agencies",
              "value": "Federal and state governments have enforcement powers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 43,
          "title": "Healthcare Reforms and Legislation Impacts",
          "data": [
            {
              "key": "Impact of ACA on pharmaceutical industry",
              "value": "The ACA significantly impacts the pharmaceutical industry by broadening access to health insurance, reducing healthcare spending growth, and imposing new taxes and fees."
            },
            {
              "key": "MDRP Changes under ACA",
              "value": "The ACA expanded manufacturers' rebate liability and increased Medicaid rebate requirements."
            },
            {
              "key": "Healthcare provider payment reductions",
              "value": "The Budget Control Act created automatic reductions to Medicare payments, including a 2.0% reduction that is set to last until 2030 except for COVID-19 related suspensions."
            },
            {
              "key": "Inflation Reduction Act of 2022",
              "value": "The IRA implemented drug price negotiations and penalties for noncompliance, affecting potential profitability for pharmaceutical manufacturers."
            },
            {
              "key": "Legal challenges to ACA",
              "value": "The ACA has faced multiple legal challenges, with ruling inconsistencies regarding its constitutionality."
            },
            {
              "key": "Future healthcare reforms impact",
              "value": "Ongoing changes to healthcare laws, including ACA adaptations, could negatively affect the healthcare industry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 44,
          "title": "Regulatory Framework for Pharmaceuticals",
          "data": [
            {
              "key": "State Level Legislation",
              "value": "Legislatures have increasingly passed legislation to control pharmaceutical product pricing, including price constraints and marketing cost disclosure."
            },
            {
              "key": "Foreign Corrupt Practices Act (FCPA)",
              "value": "The FCPA prohibits U.S. individuals from paying foreign officials to influence business decisions."
            },
            {
              "key": "Health Canada",
              "value": "Health Canada regulates drugs, requiring a Clinical Trial Application (CTA) for drug testing and maintaining licensing requirements."
            },
            {
              "key": "Market Authorization",
              "value": "Products must undergo evaluation for safety and efficacy before receiving a Drug Identification Number (DIN) and market authorization."
            },
            {
              "key": "Post-Market Surveillance",
              "value": "Authorization holders must report new safety and efficacy information after market approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 64,
          "title": "Regulatory and Litigation Risks",
          "data": [
            {
              "key": "Impermissible Product Promotion",
              "value": "Subject to liability and government fines for improper promotion."
            },
            {
              "key": "FDA Enforcement",
              "value": "FDA and other agencies enforce laws regarding product promotion."
            },
            {
              "key": "Civil and Criminal Fines",
              "value": "Federal government has levied large fines against improper promotions."
            },
            {
              "key": "False Claims Act",
              "value": "Allows individuals to bring lawsuits on behalf of the government for fraudulent claims."
            },
            {
              "key": "Litigation Risks",
              "value": "Companies may face lawsuits and civil penalties."
            },
            {
              "key": "Distribution Compliance",
              "value": "Distribution of product samples must comply with U.S. PDMA requirements."
            },
            {
              "key": "Regulatory Actions",
              "value": "FDA can request changes in promotional materials or take enforcement actions."
            },
            {
              "key": "Marketing Approval",
              "value": "Subject to ongoing obligations and regulatory reviews."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Products may be subject to numerous ongoing compliance obligations."
            },
            {
              "key": "REMS",
              "value": "Approved products may face restrictions making them not commercially viable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 65,
          "title": "FDA Regulatory Compliance and Risks",
          "data": [
            {
              "key": "Inspection Authority",
              "value": "FDA may conduct unannounced inspections."
            },
            {
              "key": "Compliance Requirements",
              "value": "Must adhere to current GMP and regulatory requirements."
            },
            {
              "key": "Pre-approval for Changes",
              "value": "Application holders must notify the FDA for pre-approval of product and manufacturing changes."
            },
            {
              "key": "Consequences of Non-compliance",
              "value": "Various outcomes including marketing restrictions and enforcement actions."
            },
            {
              "key": "Potential Issues",
              "value": "Discovery of adverse events or ineffective products may lead to sanctions."
            },
            {
              "key": "Regulatory Actions",
              "value": "The FDA may impose numerous regulatory actions including fines and warnings."
            },
            {
              "key": "Impact on Market Acceptance",
              "value": "Regulatory issues could prevent market acceptance of products."
            },
            {
              "key": "Financial Implications",
              "value": "Such events could significantly harm financial condition and stock price."
            },
            {
              "key": "FDA Policy Changes",
              "value": "Regulatory approval processes may change leading to delays."
            },
            {
              "key": "Product Name Approval Requirements",
              "value": "FDA approval needed for product names regardless of trademark status."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 74,
          "title": "Regulatory Risks and Compliance Challenges in Manufacturing",
          "data": [
            {
              "key": "FDA compliance requirements",
              "value": "Manufacturers must adhere to current GMP requirements including quality control and assurance."
            },
            {
              "key": "Consequences of non-compliance",
              "value": "Failure to meet regulatory standards may result in enforcement actions, fines, penalties, or product approval delays."
            },
            {
              "key": "Regulatory actions described",
              "value": "Actions can include warnings, clinical holds, or closure of facilities due to compliance issues."
            },
            {
              "key": "Impact on commercialization",
              "value": "Delays in obtaining regulatory approval can hinder the commercialization of product candidates."
            },
            {
              "key": "Shortage of materials",
              "value": "Manufacturers may face shortages of necessary materials for clinical trials and commercial production."
            },
            {
              "key": "Limited manufacturers",
              "value": "There are limited qualified third-party manufacturers under current GMP regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 77,
          "title": "Securities Litigation and Regulatory Compliance Risks",
          "data": [
            {
              "key": "Securities Litigation",
              "value": "Subject to ongoing and future securities litigation which may divert management time."
            },
            {
              "key": "Class Action Lawsuits",
              "value": "Two related securities class action lawsuits filed against the company."
            },
            {
              "key": "Court Information",
              "value": "U.S. District Court for the Eastern District of Pennsylvania."
            },
            {
              "key": "Case Numbers",
              "value": "2:21-cv-02725, 2:21-cv-03182, 2:21-cv-03876, 2:21-cv-04169."
            },
            {
              "key": "Current Status",
              "value": "No decision has been made by the Court on the motion to dismiss."
            },
            {
              "key": "Outcome Prediction",
              "value": "Cannot predict the outcome of ongoing lawsuits."
            },
            {
              "key": "Health Compliance Risks",
              "value": "Potential penalties if failing to comply with healthcare laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 78,
          "title": "Regulatory and Legal Compliance Risks",
          "data": [
            {
              "key": "Potential Governmental Penalties",
              "value": "Penalties, including civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, suspension and debarment from government contracts, refusal of orders under existing government contracts."
            },
            {
              "key": "Healthcare Legislative Changes",
              "value": "Legislative and regulatory changes affecting the healthcare system, including cost-containment programs, price controls, and reimbursement restrictions."
            },
            {
              "key": "Affordable Care Act",
              "value": "Changes to the way healthcare is financed by both governmental and private insurers, including expansions of manufacturers' rebate liability."
            },
            {
              "key": "Medicare Reimbursement Reduction Potential",
              "value": "Potential reductions in Medicare reimbursement levels affecting private payers."
            },
            {
              "key": "Long-term Medicare Sequester",
              "value": "2.0% Medicare sequester reductions effective through 2030, with various legislative impacts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 79,
          "title": "Impact of Healthcare Legislation on Financial Condition and Business Operations",
          "data": [
            {
              "key": "Healthcare Legislation",
              "value": "IRA and ACA affect on pricing and reimbursement"
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Potential misconduct leading to penalties and reputational harm"
            },
            {
              "key": "Litigation History",
              "value": "Challenges to ACA constitutionality"
            },
            {
              "key": "Future Healthcare Reforms",
              "value": "Predictable impact of future regulations on product pricing and reimbursement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 80,
          "title": "Legal and Regulatory Risks Related to Operations",
          "data": [
            {
              "key": "Summary",
              "value": "The section discusses potential legal and regulatory risks that could adversely affect business operations and financial condition."
            },
            {
              "key": "Key Laws",
              "value": "Anti-corruption laws, Bribery Act, FCPA, export control laws."
            },
            {
              "key": "Implications of Non-compliance",
              "value": "Criminal and civil penalties, legal expenses, restrictions on business."
            },
            {
              "key": "Operational Expansion Risks",
              "value": "Expanding operations may require additional resources for compliance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 83,
          "title": "Intellectual Property Litigation Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The document outlines the risks associated with potential litigation regarding infringement of intellectual property rights in the biotechnology and pharmaceutical industries."
            },
            {
              "key": "Potential Impact",
              "value": "Infringement claims could adversely affect the company's commercialization efforts and financial viability."
            },
            {
              "key": "Legal Proceedings",
              "value": "The company may become involved in various legal proceedings, including infringement litigation claims, which are costly and time-consuming."
            },
            {
              "key": "Licensing Risks",
              "value": "If found infringing, the company may need to obtain licenses which could be costly or not obtainable on reasonable terms."
            },
            {
              "key": "Non-compliance Risks",
              "value": "Failure to comply with procedural requirements could lead to the loss of patent rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 84,
          "title": "Intellectual Property Rights and Agreements Overview",
          "data": [
            {
              "key": "Intellectual Property Agreements",
              "value": "Our product candidates are protected by patents in-licensed from other companies."
            },
            {
              "key": "Licensing Risks",
              "value": "If licensors fail to maintain patents or agreements, our competitive position may be harmed."
            },
            {
              "key": "Bayh-Dole Act Compliance",
              "value": "Our intellectual property may be subject to federal regulations, limiting exclusive rights."
            },
            {
              "key": "Patent Prosecution Management",
              "value": "We manage patent prosecution for some agreements but may lose control over others."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 85,
          "title": "U.S. Government Rights in Inventions Developed Using Government Funded Program",
          "data": [
            {
              "key": "Program Rights",
              "value": "U.S. governmentâs right to a non-exclusive, non-transferable, irrevocable worldwide license for governmental purpose."
            },
            {
              "key": "Bayh-Dole Act",
              "value": "Gives the government rights to require exclusive licenses or take title if inventions are not disclosed or patented."
            },
            {
              "key": "Manufacturing Preference",
              "value": "Products subject to the Bayh-Dole Act must be manufactured substantially in the U.S., with conditions for waiver."
            },
            {
              "key": "Implication of Agreement Failure",
              "value": "Failing to comply with obligations may result in loss of intellectual property rights."
            },
            {
              "key": "Licensing Arrangements",
              "value": "Agreements impose royalties, financial obligations, and discretion on compliance."
            },
            {
              "key": "Termination Risks",
              "value": "Potential termination of agreements could harm development, manufacturing, and marketing capabilities."
            },
            {
              "key": "Dispute Risks",
              "value": "Complex agreements may lead to disputes affecting perceived rights and obligations."
            },
            {
              "key": "International Protection",
              "value": "Challenges in maintaining global patent rights and protections."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 86,
          "title": "Intellectual Property Litigation Risks",
          "data": [
            {
              "key": "Risk of Infringement",
              "value": "Proceedings to enforce intellectual property rights may lead to substantial costs and risk of invalidation."
            },
            {
              "key": "Impact of Litigation",
              "value": "Intellectual property litigation could cause distraction from core business responsibilities and increase operating losses."
            },
            {
              "key": "Claims from Third Parties",
              "value": "Possible claims of misappropriation of intellectual property by third parties."
            },
            {
              "key": "Compulsory Licensing Laws",
              "value": "Countries with compulsory licensing laws may compel patent owners to grant licenses, diminishing patent value."
            },
            {
              "key": "Employee Misappropriation Risk",
              "value": "Claims may arise from former employers of employees or contractors regarding proprietary information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 88,
          "title": "General Risk Factors on Stockholder Actions and Court Jurisdiction",
          "data": [
            {
              "key": "Approval Requirements for Amendments",
              "value": "At least 66-2/3% of shares entitled to vote required to adopt, amend, or repeal certain provisions."
            },
            {
              "key": "Prohibition on Written Consent",
              "value": "Stockholder action must be taken at an annual or special meeting."
            },
            {
              "key": "Exclusive Forum Provision",
              "value": "Court of Chancery of the State of Delaware designated as exclusive forum for certain actions."
            },
            {
              "key": "Special Meeting Requirements",
              "value": "May only be called by specific executives or the Board, potentially delaying actions."
            },
            {
              "key": "Advance Notice Procedures",
              "value": "Stockholders must comply with procedures to nominate candidates or propose matters."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Subject to Section 203 of the Delaware General Corporation Law."
            },
            {
              "key": "Risk of Lawsuits",
              "value": "Choice of forum provisions may deter stockholder lawsuits."
            },
            {
              "key": "Volatility of Stock Prices",
              "value": "Trading prices could be highly volatile, influencing investor decisions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 91,
          "title": "Environmental and Safety Compliance Risks",
          "data": [
            {
              "key": "Environmental Laws Compliance Impact",
              "value": "The company may face significant fines, penalties, or costs due to non-compliance with environmental regulations."
            },
            {
              "key": "Hazardous Materials Use",
              "value": "Operations involve hazardous materials, which pose risks of contamination and injury."
            },
            {
              "key": "Internal Control Over Financial Reporting",
              "value": "Failure to maintain effective internal controls may impair financial reporting accuracy and affect stock price."
            },
            {
              "key": "Potential Liabilities",
              "value": "Liabilities from environmental laws could exceed company resources."
            },
            {
              "key": "Workers' Compensation Insurance Limitations",
              "value": "Current coverage may not be adequate for all potential liabilities."
            },
            {
              "key": "Impact on Research and Development",
              "value": "Compliance with environmental regulations may impair research and product development efforts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 93,
          "title": "Risks Related to Cybersecurity and Data Protection Laws",
          "data": [
            {
              "key": "Cybersecurity Risks",
              "value": "Companies engaged in biotechnology development, particularly in COVID-19 therapeutic and vaccine products, face risks of cyberattacks."
            },
            {
              "key": "Data Protection Compliance",
              "value": "The organization processes personal health data during clinical trials."
            },
            {
              "key": "Specific Laws Mentioned",
              "value": "California Consumer Privacy Act (CCPA), California Privacy Rights Act (CPRA), EU's General Data Protection Regulation (GDPR)."
            },
            {
              "key": "Risks Associated",
              "value": "Potential exposure to civil and criminal liabilities due to failure to comply with data protection laws."
            },
            {
              "key": "Impact of Non-Compliance",
              "value": "Failure to comply with evolving privacy laws could negatively affect financial condition."
            },
            {
              "key": "Social Media Risks",
              "value": "Potential for dissemination of inaccurate information via social media, leading to regulatory actions."
            },
            {
              "key": "Evolving ESG Expectations",
              "value": "Increasing investor and stakeholder focus on Environmental, Social, and Governance (ESG) issues may expose the organization to reputational risks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 94,
          "title": "Legal Proceedings",
          "data": [
            {
              "key": "discussion",
              "value": "For a discussion of legal proceedings, see Note 15 in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. This discussion is incorporated herein by reference."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 141,
          "title": "Securities Class Action Lawsuits",
          "data": [
            {
              "key": "case_number",
              "value": "2:21-cv-04169"
            },
            {
              "key": "filing_date",
              "value": "September 2021"
            },
            {
              "key": "claims",
              "value": "breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, contribution for violations of Sections 10(b) and 21(d) of the Exchange Act"
            },
            {
              "key": "defendant",
              "value": "Ocugen"
            },
            {
              "key": "court_order_date",
              "value": "April 2022"
            },
            {
              "key": "outcome_materiality",
              "value": "No assessment can be made at this time."
            },
            {
              "key": "loss_estimation",
              "value": "No information indicating probable loss."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 72,
          "title": "Supply Chain Disruptions",
          "data": [
            {
              "key": "Potential Risks",
              "value": "Reliance on third-party service providers may affect competitive position."
            },
            {
              "key": "Regulatory Requirements",
              "value": "Need to report financial interests and register clinical trials."
            },
            {
              "key": "External Dependencies",
              "value": "Dependence on third parties for manufacturing and supply of COVAXIN."
            },
            {
              "key": "Agreements and Partnerships",
              "value": "Entering into agreements with CanSinoBIO and Bharat Biotech."
            },
            {
              "key": "Transition Challenges",
              "value": "Challenges in transitioning manufacturing from Bharat Biotech to Jubilant HollisterStier."
            },
            {
              "key": "Manufacturing Complexities",
              "value": "Difficulties in producing batches, including potential equipment failure."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 15,
          "title": "Gene Expression Analysis and Treatment Options",
          "data": [
            {
              "key": "GFP_label",
              "value": "AAV8-Nr2e3-GFP"
            },
            {
              "key": "Assessment_days",
              "value": "post-natal day 7 and post-natal day 30"
            },
            {
              "key": "Retinal_transcription_factors_improved",
              "value": "Nr2e3, Nrl, Rora, Thrb, Nr1d1, Crx"
            },
            {
              "key": "Gene_expression_changes",
              "value": "significant decrease in expression reversed following Nr2e3 therapy"
            },
            {
              "key": "Therapy_type",
              "value": "Gene replacement and modifier gene therapy"
            },
            {
              "key": "Conditions_affected",
              "value": "RP and LCA"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 21,
          "title": "Clinical Trials and Regulatory Pathway for COVAXIN",
          "data": [
            {
              "key": "Clinical Trials Phase 1 and Phase 2",
              "value": "Conducted in India to evaluate safety and immunogenicity of COVAXIN."
            },
            {
              "key": "Phase 3 clinical trial",
              "value": "Enrolled 25,798 adults; efficacy against severe COVID-19 was reported at 93.4%."
            },
            {
              "key": "Neutralizing Potential",
              "value": "COVAXIN demonstrated potential against multiple COVID-19 variants, including Omicron."
            },
            {
              "key": "COVAXIN in children",
              "value": "Assess the immunity of COVAXIN in children ages two to 18 years."
            },
            {
              "key": "Regulatory Pathway in the United States",
              "value": "Top-line results from Phase 2/3 clinical trial evaluated immune response in U.S. adults."
            },
            {
              "key": "Commercial Rights",
              "value": "Bharat Biotech holds rights to commercialize COVAXIN in Canada and Mexico."
            },
            {
              "key": "Health Canada Submission",
              "value": "Completed rolling submission in July 2021; withdrew NDS in August 2022."
            },
            {
              "key": "Emergency Use Authorization in Mexico",
              "value": "COFEPRIS authorized emergency use for COVAXIN for adults."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 92,
          "title": "Potential Product Liability Exposure and Cybersecurity Risks",
          "data": [
            {
              "key": "Product Liability Exposure",
              "value": "We face potential product liability exposure, and... we may incur substantial liability for our product candidates."
            },
            {
              "key": "Cybersecurity Risks",
              "value": "Our internal computer systems... are vulnerable to cybersecurity breaches and damage from computer viruses."
            },
            {
              "key": "Insurance Coverage",
              "value": "While we currently hold product liability insurance coverage... the amount of that coverage may not be adequate."
            },
            {
              "key": "Risks From Claims",
              "value": "A successful product liability claim or series of claims... could cause our stock price to fall."
            },
            {
              "key": "Data Privacy Risks",
              "value": "We face risks related to our collection and use of data, which could result in investigations, inquiries, litigation, fines."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 11,
    "EUR": 8,
    "AUD": 16,
    "CAD": 5,
    "ZAR": 2
  },
  "sha1": "36dd058d3237202cbb94139611c8b8a35ff8c158"
}